117 results on '"Mao, Ying"'
Search Results
2. Rapid detection of IDH mutations in gliomas by intraoperative mass spectrometry.
- Author
-
Hua W, Zhang W, Brown H, Wu J, Fang X, Shahi M, Chen R, Zhang H, Jiao B, Wang N, Xu H, Fu M, Wang X, Zhang J, Zhang X, Wang Q, Zhu W, Ye D, Garcia DM, Chaichana K, Cooks RG, Ouyang Z, Mao Y, and Quinones-Hinojosa A
- Subjects
- Humans, Tandem Mass Spectrometry methods, Glutarates metabolism, Mass Spectrometry methods, Glutamic Acid metabolism, Glutamic Acid genetics, Glioma genetics, Glioma surgery, Glioma pathology, Isocitrate Dehydrogenase genetics, Mutation, Brain Neoplasms genetics, Brain Neoplasms surgery, Brain Neoplasms pathology
- Abstract
The development and performance of two mass spectrometry (MS) workflows for the intraoperative diagnosis of isocitrate dehydrogenase (IDH) mutations in glioma is implemented by independent teams at Mayo Clinic, Jacksonville, and Huashan Hospital, Shanghai. The infiltrative nature of gliomas makes rapid diagnosis necessary to guide the extent of surgical resection of central nervous system (CNS) tumors. The combination of tissue biopsy and MS analysis used here satisfies this requirement. The key feature of both described methods is the use of tandem MS to measure the oncometabolite 2-hydroxyglutarate (2HG) relative to endogenous glutamate (Glu) to characterize the presence of mutant tumor. The experiments i) provide IDH mutation status for individual patients and ii) demonstrate a strong correlation of 2HG signals with tumor infiltration. The measured ratio of 2HG to Glu correlates with IDH-mutant (IDH-mut) glioma ( P < 0.0001) in the tumor core data of both teams. Despite using different ionization methods and different mass spectrometers, comparable performance in determining IDH mutations from core tumor biopsies was achieved with sensitivities, specificities, and accuracies all at 100%. None of the 31 patients at Mayo Clinic or the 74 patients at Huashan Hospital were misclassified when analyzing tumor core biopsies. Robustness of the methodology was evaluated by postoperative re-examination of samples. Both teams noted the presence of high concentrations of 2HG at surgical margins, supporting future use of intraoperative MS to monitor for clean surgical margins. The power of MS diagnostics is shown in resolving contradictory clinical features, e.g., in distinguishing gliosis from IDH-mut glioma., Competing Interests: Competing interests statement:Z.O. is the founder of PurSpec Technologies, which is developing miniature mass spectrometry systems.
- Published
- 2024
- Full Text
- View/download PDF
3. Effect of high-field iMRI guided resection in cerebral glioma surgery: A randomized clinical trial.
- Author
-
Li Z, Song Y, Farrukh Hameed NU, Yuan S, Wu S, Gong X, Zhuang D, Lu J, Zhu F, Qiu T, Zhang J, Aibaidula A, Geng X, Yang Z, Tang W, Chen H, Zhou L, Mao Y, and Wu J
- Subjects
- Humans, Retrospective Studies, Monitoring, Intraoperative methods, Neurosurgical Procedures adverse effects, Neurosurgical Procedures methods, Magnetic Resonance Imaging methods, Brain Neoplasms diagnostic imaging, Brain Neoplasms surgery, Glioma diagnostic imaging, Glioma surgery
- Abstract
Background: Extent of resection (EOR) in glioma contributes to longer survival. The purpose of NCT01479686 was to prove whether intraoperative magnetic resonance imaging (iMRI) increases EOR in glioma surgery and benefit survival., Methods: Patients were randomized (1:1) to receive the iMRI (n = 161) or the conventional neuronavigation (n = 160). The primary endpoint was gross total resection (GTR); secondary outcomes reported were progression-free survival (PFS), overall survival (OS), and safety., Results: 188 high-grade gliomas (HGGs) and 133 low-grade gliomas (LGGs) were enrolled. GTR was 83.85% in the iMRI group vs. 50.00% in the control group (P < 0.0001). In 321 patients, the median PFS (mPFS) was 65.12 months in the iMRI group and 61.01 months in the control group (P = 0.0202). For HGGs, mPFS was improved in the iMRI group (19.32 vs. 13.34 months, P = 0.0015), and a trend of superior OS compared with control was observed (29.73 vs. 25.33 months, P = 0.1233). In the predefined eloquent area HGG subgroup, mPFS, and mOS were 20.47 months and 33.58 months in the iMRI vs. 12.21 months and 21.16 months in the control group (P = 0.0098; P = 0.0375, respectively). From the exploratory analyses of HGGs, residual tumor volume (TV) < 1.0 cm
3 decreased the risk of survival (mPFS: 18.99 vs. 9.43 months, P = 0.0055; mOS: 29.77 vs. 18.10 months, P = 0.0042). LGGs with preoperative (pre-OP) TV > 43.1 cm3 and postoperative (post-OP) TV > 4.6 cm3 showed worse OS (P= 0.0117) CONCLUSIONS: It showed that iMRI significantly increased EOR and indicated survival benefits for HGGs, particularly eloquent HGGs. Residual TV in either HGGs or LGGs is a prognostic factor for survival., Competing Interests: Declaration of Competing Interest All authors have declared no conflicts of interest., (Copyright © 2024 Elsevier Ltd. All rights reserved.)- Published
- 2024
- Full Text
- View/download PDF
4. Distinct immune escape and microenvironment between RG-like and pri-OPC-like glioma revealed by single-cell RNA-seq analysis.
- Author
-
Xian W, Asad M, Wu S, Bai Z, Li F, Lu J, Zu G, Brintnell E, Chen H, Mao Y, Zhou G, Liao B, Wu J, Wang E, and You L
- Subjects
- Humans, Ependymoglial Cells metabolism, Ependymoglial Cells pathology, Single-Cell Gene Expression Analysis, Mutation, Tumor Microenvironment genetics, Receptor-Like Protein Tyrosine Phosphatases, Class 5 genetics, Brain Neoplasms genetics, Brain Neoplasms pathology, Glioma genetics, Glioma metabolism, Glioma pathology
- Abstract
The association of neurogenesis and gliogenesis with glioma remains unclear. By conducting single-cell RNA-seq analyses on 26 gliomas, we reported their classification into primitive oligodendrocyte precursor cell (pri-OPC)-like and radial glia (RG)-like tumors and validated it in a public cohort and TCGA glioma. The RG-like tumors exhibited wild-type isocitrate dehydrogenase and tended to carry EGFR mutations, and the pri-OPC-like ones were prone to carrying TP53 mutations. Tumor subclones only in pri-OPC-like tumors showed substantially down-regulated MHC-I genes, suggesting their distinct immune evasion programs. Furthermore, the two subgroups appeared to extensively modulate glioma-infiltrating lymphocytes in distinct manners. Some specific genes not expressed in normal immune cells were found in glioma-infiltrating lymphocytes. For example, glial/glioma stem cell markers OLIG1/PTPRZ1 and B cell-specific receptors IGLC2/IGKC were expressed in pri-OPC-like and RG-like glioma-infiltrating lymphocytes, respectively. Their expression was positively correlated with those of immune checkpoint genes (e.g., LGALS33) and poor survivals as validated by the increased expression of LGALS3 upon IGKC overexpression in Jurkat cells. This finding indicated a potential inhibitory role in tumor-infiltrating lymphocytes and could provide a new way of cancer immune evasion., (© 2023. The Author(s).)
- Published
- 2024
- Full Text
- View/download PDF
5. Neurosurgical application of pineal region tumor resection with 3D 4K exoscopy via infratentorial approach: a retrospective cohort study.
- Author
-
Hua W, Zhang X, Wang Q, Qiu T, Yang Z, Wang X, Xu H, Zhang J, Yu G, Fu M, Chen L, Zhu W, and Mao Y
- Subjects
- Male, Female, Humans, Adult, Retrospective Studies, Treatment Outcome, Neoplasm Recurrence, Local surgery, Ventriculostomy adverse effects, Ventriculostomy methods, Pinealoma surgery, Pinealoma complications, Pinealoma pathology, Pineal Gland surgery, Pineal Gland pathology, Glioma surgery, Third Ventricle pathology, Third Ventricle surgery, Hydrocephalus etiology, Hydrocephalus surgery, Brain Neoplasms surgery
- Abstract
Background: The pineal region tumors are challenging for neurosurgeons and can lead to secondary hydrocephalus. The introduction of the exoscope has provided clinical interventions with high image quality and an ergonomic system for pineal region tumor operations. In this study, the authors describe the exoscopic approach used to facilitate the surgical resection of pineal region tumors and relieve hydrocephalus., Materials and Methods: In this retrospective cohort study, we consecutively reviewed the clinical and radiological data of 25 patients with pineal region lesions who underwent three-dimensional exoscopic tumor resection at a single center., Results: The patient cohort consisted of 16 males and 9 females, with an average age of 34.6 years (range, 6-62 years; 8 cases aged ≤18). Pathological examination confirmed eight pineal gland tumors, four gliomas, nine germ cell neoplasms, two ependymomas, and two metastatic tumors. Preoperative hydrocephalus was present in 23 patients. Prior to tumor resection, external ventricular drainage (EVD) with Ommaya reservoir implantation was performed in 17 patients. Two patients received preoperative endoscopic third ventriculostomy (ETV), and five patients received a ventriculoperitoneal (VP) shunt, including one who received both procedures. Gross total resection was achieved in 19 patients (76%) in the 'head-up' park bench position using the exoscope. Eight patients (31.6%) with third ventricle invasion received subtotal resection, mainly in glioma cases, which was higher than those without invasion (0%), but not statistically significant ( P =0.278, Fisher's exact test). No new neurological dysfunction was observed after surgery. Two patients (8%) developed intracranial and pulmonary infections, and two patients (8%) suffered from pneumothorax. Hydrocephalus was significantly relieved in all patients postoperatively, and four patients with relapse hydrocephalus were cured during the long-term follow-up. Postoperative adjuvant management was recommended for indicated patients, and a mean follow-up of 24.8±14.3 months showed a satisfied outcome., Conclusions: The exoscope is a useful tool for pineal region tumor resection and hydrocephalus relief, particularly with posterior third ventricle invasion, as total resection could be achieved without obvious complication. The special superiority of the exoscope for the indicated pineal region tumors should be highlighted., (Copyright © 2023 The Author(s). Published by Wolters Kluwer Health, Inc.)
- Published
- 2023
- Full Text
- View/download PDF
6. Intra-Operative Definition of Glioma Infiltrative Margins by Visualizing Immunosuppressive Tumor-Associated Macrophages.
- Author
-
Cao C, Yin H, Yang B, Yue Q, Wu G, Gu M, Zhang Y, Fan Y, Dong X, Wang T, Wang C, Zhu X, Mao Y, Zhang XY, Lei Z, and Li C
- Subjects
- Mice, Humans, Rats, Animals, Fluorescent Dyes, Mannose Receptor, Tumor-Associated Macrophages, Glioma metabolism
- Abstract
Accurate delineation of glioma infiltrative margins remains a challenge due to the low density of cancer cells in these regions. Here, a hierarchical imaging strategy to define glioma margins by locating the immunosuppressive tumor-associated macrophages (TAMs) is proposed. A pH ratiometric fluorescent probe CP2-M that targets immunosuppressive TAMs by binding to mannose receptor (CD206) is developed, and it subsequently senses the acidic phagosomal lumen, resulting in a remarkable fluorescence enhancement. With assistance of CP2-M, glioma xenografts in mouse models with a tumor-to-background ratio exceeding 3.0 for up to 6 h are successfully visualized. Furthermore, by intra-operatively mapping the pH distribution of exposed tissue after craniotomy, the glioma allograft in rat models is precisely excised. The overall survival of rat models significantly surpasses that achieved using clinically employed fluorescent probes. This work presents a novel strategy for locating glioma margins, thereby improving surgical outcomes for tumors with infiltrative characteristics., (© 2023 The Authors. Advanced Science published by Wiley-VCH GmbH.)
- Published
- 2023
- Full Text
- View/download PDF
7. LILRB3 suppresses immunity in glioma and is associated with poor prognosis.
- Author
-
Zhuang Q, Liu Y, Wang H, Lin Z, Sun L, Liu Y, Lyu Y, Chen L, Yang H, and Mao Y
- Subjects
- Humans, Prognosis, Receptors, Immunologic, Antigens, CD, Glioma genetics, Brain Neoplasms genetics
- Published
- 2023
- Full Text
- View/download PDF
8. Cell Cycle-Related FAM64A Could be Activated by TGF-β Signaling to Promote Glioma Progression.
- Author
-
Fu M, Zhang J, Zhang L, Feng Y, Fang X, Zhang J, Wen W, Hua W, and Mao Y
- Subjects
- Humans, Cell Cycle genetics, Cell Proliferation genetics, Cell Division, Epithelial-Mesenchymal Transition genetics, Transforming Growth Factor beta metabolism, Cell Movement genetics, Cell Line, Tumor, Gene Expression Regulation, Neoplastic, Glioma pathology, Brain Neoplasms pathology
- Abstract
Gliomas are aggressive brain tumors characterized by uncontrolled cell proliferation. FAM64A, a cell cycle-related gene, has been found to promote cell proliferation in various tumors, including gliomas. However, the regulatory mechanism and clinical significance of FAM64A in gliomas remain unclear. In this study, we investigated FAM64A expression in gliomas with different grades and constructed FAM64A silenced cell lines to study its functions. Our results demonstrated that FAM64A was highly expressed in glioblastoma (P < 0.001) and associated with a poor prognosis (P < 0.001). Expression profiles at the single-cell resolution indicated FAM64A could play a role in a cell-cycle-dependent way to promote glioma cell proliferation. We further observed that FAM64A silencing in glioma cells resulted in disrupted proliferation and migration ability, and increased cell accumulation in the G2/M phase (P = 0.034). Additionally, TGF-β signaling upregulates FAM64A expression, and SMAD4 and FAM64A co-localize in high-grade glioma tissues. We found FAM64A knockdown inhibited TGF-β-induced epithelial-mesenchymal transition in glioma. Our findings suggest that FAM64A could serve as a diagnostic and therapeutic target in gliomas., (© 2023. The Author(s), under exclusive licence to Springer Science+Business Media, LLC, part of Springer Nature.)
- Published
- 2023
- Full Text
- View/download PDF
9. A phase I dose-escalation study of SYHA1813, a VEGFR and CSF1R inhibitor, in patients with recurrent High-Grade Gliomas or Advanced Solid Tumors.
- Author
-
Kang Z, Li S, Lin Y, Li Y, Mao Y, Zhang J, Lei T, Wang H, Su Y, Yang Y, Qiu J, and Li W
- Subjects
- Humans, Female, Vascular Endothelial Growth Factor A, Placenta Growth Factor therapeutic use, Neoplasm Recurrence, Local drug therapy, Receptors, Colony-Stimulating Factor, Maximum Tolerated Dose, Neoplasms drug therapy, Glioma drug therapy, Hypertension
- Abstract
SYHA1813 is a potent multikinase inhibitor that targets vascular endothelial growth factor receptors (VEGFRs)/colony-stimulating factor 1 receptor (CSF1R). This study aimed to evaluate the safety, pharmacokinetics (PK), and antitumor activity of escalating doses of SYHA1813 in patients with recurrent high-grade gliomas (HGGs) or advanced solid tumors. This study adopted a combination of accelerated titration and a 3 + 3 design for dose escalation, with a starting dose of 5 mg once daily. The dose escalation continued at successive dose levels until the maximum tolerated dose (MTD) was determined. A total of 14 patients were enrolled and treated, including 13 with WHO grade III or IV gliomas and 1 with colorectal cancer. Two patients experienced dose-limiting toxicities (grade 4 hypertension and grade 3 mucositis oral) at 30 mg SYHA1813. The MTD was defined as 15 mg once daily. Hypertension (n = 6, 42.9%) was the most frequent treatment-related adverse event. Among evaluable patients (n = 10), 2 (20%) patients achieved partial response, and 7 (70%) had stable disease. The exposure increased with increasing doses within the studied dose range of 5 to 30 mg. Biomarker assessments demonstrated significant reductions in the levels of soluble VEGFR2 (P = .0023) and increases in the levels of VEGFA (P = .0092) and placental growth factor (P = .0484). The toxicities of SYHA1813 were manageable, and encouraging antitumor efficacy was observed in patients with recurrent malignant glioma. This study is registered with the Chinese Clinical Trial Registry ( www.chictr.org.cn/index.aspx ; identifier ChiCTR2100045380)., (© 2023. The Author(s).)
- Published
- 2023
- Full Text
- View/download PDF
10. The Oncogenesis of Glial Cells in Diffuse Gliomas and Clinical Opportunities.
- Author
-
Zhuang Q, Yang H, and Mao Y
- Subjects
- Humans, Neuroglia metabolism, Carcinogenesis genetics, Carcinogenesis metabolism, Carcinogenesis pathology, Microglia metabolism, Tumor Microenvironment, Glioma metabolism, Neural Stem Cells metabolism, Brain Neoplasms genetics, Brain Neoplasms metabolism
- Abstract
Glioma is the most common and lethal intrinsic primary tumor of the brain. Its controversial origins may contribute to its heterogeneity, creating challenges and difficulties in the development of therapies. Among the components constituting tumors, glioma stem cells are highly plastic subpopulations that are thought to be the site of tumor initiation. Neural stem cells/progenitor cells and oligodendrocyte progenitor cells are possible lineage groups populating the bulk of the tumor, in which gene mutations related to cell-cycle or metabolic enzymes dramatically affect this transformation. Novel approaches have revealed the tumor-promoting properties of distinct tumor cell states, glial, neural, and immune cell populations in the tumor microenvironment. Communication between tumor cells and other normal cells manipulate tumor progression and influence sensitivity to therapy. Here, we discuss the heterogeneity and relevant functions of tumor cell state, microglia, monocyte-derived macrophages, and neurons in glioma, highlighting their bilateral effects on tumors. Finally, we describe potential therapeutic approaches and targets beyond standard treatments., (© 2022. The Author(s).)
- Published
- 2023
- Full Text
- View/download PDF
11. Intelligent SERS Navigation System Guiding Brain Tumor Surgery by Intraoperatively Delineating the Metabolic Acidosis.
- Author
-
Jin Z, Yue Q, Duan W, Sui A, Zhao B, Deng Y, Zhai Y, Zhang Y, Sun T, Zhang GP, Han L, Mao Y, Yu J, Zhang XY, and Li C
- Subjects
- Animals, Humans, Margins of Excision, Spectrum Analysis, Raman, Acidosis, Brain Neoplasms surgery, Glioma pathology, Glioma surgery
- Abstract
Surgeons face challenges in intraoperatively defining margin of brain tumors due to its infiltrative nature. Extracellular acidosis caused by metabolic reprogramming of cancer cells is a reliable marker for tumor infiltrative regions. Although the acidic margin-guided surgery shows promise in improving surgical prognosis, its clinical transition is delayed by having the exogenous probes approved by the drug supervision authority. Here, an intelligent surface-enhanced Raman scattering (SERS) navigation system delineating glioma acidic margins without administration of exogenous probes is reported. With assistance of this system, the metabolites at the tumor cutting edges can be nondestructively transferred within a water droplet to a SERS chip with pH sensitivity. Homemade deep learning model automatically processes the Raman spectra collected from the SERS chip and delineates the pH map of tumor resection bed with increased speed. Acidity correlated cancer cell density and proliferation level are demonstrated in tumor cutting edges of animal models and excised tissues from glioma patients. The overall survival of animal models post the SERS system guided surgery is significantly increased in comparison to the conventional strategy used in clinical practice. This SERS system holds the promise in accelerating clinical transition of acidic margin-guided surgery for solid tumors with infiltrative nature., (© 2022 The Authors. Advanced Science published by Wiley-VCH GmbH.)
- Published
- 2022
- Full Text
- View/download PDF
12. Reprogramming the immunosuppressive microenvironment of IDH1 wild-type glioblastoma by blocking Wnt signaling between microglia and cancer cells.
- Author
-
Fan D, Yue Q, Chen J, Wang C, Yu R, Jin Z, Yin S, Wang Q, Chen L, Liao X, Peng C, Zhang J, Cao Z, Mao Y, Huang R, Chen L, and Li C
- Subjects
- Animals, CD8-Positive T-Lymphocytes metabolism, Humans, Isocitrate Dehydrogenase genetics, Mice, Microglia metabolism, Tumor Microenvironment, Wnt Signaling Pathway, Glioblastoma drug therapy, Glioma drug therapy
- Abstract
The vast majority (>90%) of glioblastoma (GBM) patients belong to the isocitrate dehydrogenase 1 wild type (IDH1
WT ) group which exhibits a poor prognosis with a median survival of less than 15 months. This study demonstrated numerous immunosuppressive genes as well as β-catenin gene, pivotal for Wnt/β-catenin signaling, were upregulated in 206 IDH1WT glioma patients using the Chinese Glioma Genome Atlas (CGGA) database. The increase in microglia with an immunosuppressive phenotype and the overexpression of β-catenin protein were further verified in IDH1WT GBM patients and IDH1WT GL261 glioma allografts. Subsequently, we found that IDH1WT GL261 cell-derived conditioned medium activated Wnt/β-catenin signaling in primary microglia and triggered their transition to an immunosuppressive phenotype. Blocking Wnt/β-catenin signaling not only attenuated microglial polarization to the immunosuppressive subtype but also reactivated immune responses in IDH1WT GBM allografts by simultaneously enhancing cytotoxic CD8+ T cell infiltration and downregulating regulatory T cells. Positron emission tomography imaging demonstrated enhanced proinflammatory activities in IDH1WT GBM allografts after the blockade of Wnt signaling. Finally, gavage administration of a Wnt signaling inhibitor significantly restrained tumor proliferation and improved the survival of model mice bearing IDH1WT GBM allografts. Depletion of CD8+ T cells remarkably abrogated the therapeutic efficacy induced by the Wnt signaling inhibitor. Overall, the present work indicates that the crosstalk between IDH1WT glioma cells and immunosuppressive microglia is important in maintaining the immunosuppressive glioma microenvironment. Blocking Wnt/β-catenin signaling is a promising complement for IDH1WT GBM treatment by improving the hostile immunosuppressive microenvironment., (© 2021 The Author(s). Published with license by Taylor & Francis Group, LLC.)- Published
- 2021
- Full Text
- View/download PDF
13. How I do it? Gravity-assisted endoscopic cingulate gyrus glioma resection.
- Author
-
Yang Z, Song J, Zhu W, and Mao Y
- Subjects
- Brain Mapping, Brain Neoplasms diagnostic imaging, Glioma diagnostic imaging, Gyrus Cinguli diagnostic imaging, Humans, Magnetic Resonance Imaging, Male, Middle Aged, Postoperative Complications etiology, Brain Neoplasms surgery, Endoscopy, Glioma surgery, Gravitation, Gyrus Cinguli surgery
- Abstract
Background: The cingulate gyrus is part of the limbic system with extensive connectivity to different anatomical and functional areas. The traditional transcortical approach for a cingulate gyrus glioma contains high risk of transient or even irreversible postoperative hemiplegia., Method: We present a case of gravity-assisted, fully endoscopic resection of a cingulate gyrus glioma with improvement of motor dysfunction while preserving the paracentral lobule, corticospinal tracts, and supplementary motor area., Conclusion: This case demonstrates the value of gravity-assisted endoscopic resection in the dominant cingulate gyrus tumor which is surrounded by eloquent parenchyma.
- Published
- 2021
- Full Text
- View/download PDF
14. A Novel Intraoperative Brain Mapping Integrated Task-Presentation Platform.
- Author
-
Hameed NUF, Zhao Z, Zhang J, Bu L, Zhou Y, Jin L, Bai H, Li W, Tang J, Lu J, Wu J, and Mao Y
- Subjects
- Brain Mapping, Electric Stimulation, Humans, Wakefulness, Brain Neoplasms diagnostic imaging, Brain Neoplasms surgery, Glioma
- Abstract
Background: To be efficient, intraoperative task-presentation systems must accurately present various language and cognitive tasks to patients undergoing awake surgery, and record behavioral data without compromising convenience of surgery., Objective: To present an integrated brain mapping task-presentation system we developed and evaluate its effectiveness in intraoperative task presentation., Methods: The Brain Mapping Interactive Stimulation System (Brain MISS) is a flexible task presentation system that adjusts for patient comfort, needs of the surgeon, and operating team, with multivideo recording for patients' behavior. A total of 48 patients from 3 centers underwent intraoperative language task test during awake brain surgery with the Brain MISS. Each patient was assigned 5 questions each on picture naming, reading, and listening comprehension before and during awake surgeries. The accuracy of intraoperative stimulus-response (without electrical stimulation) was recorded. The Brain MISS was to be considered effective, if the lower limit of 95% CI of patients' intraoperative response was ≥80% and also if the accuracy of intraoperative response of all patients was statistically higher than 80%., Results: All patients successfully underwent intraoperative assessment with the Brain MISS. The overall accuracy of stimulus response was 95.8% (95% CI 90.18%-100.00%), with the lower limit being higher than 80% and the response accuracy also significantly being higher than 80% in all patients (P = .006)., Conclusion: The Brain MISS is a portable and effective system for presenting and streamlining complicated language and cognitive tasks during awake surgery. It can also record standardized patient response data for neuroscientific research., (© Congress of Neurological Surgeons 2021.)
- Published
- 2021
- Full Text
- View/download PDF
15. Clinical practice guidelines for the management of adult diffuse gliomas.
- Author
-
Jiang T, Nam DH, Ram Z, Poon WS, Wang J, Boldbaatar D, Mao Y, Ma W, Mao Q, You Y, Jiang C, Yang X, Kang C, Qiu X, Li W, Li S, Chen L, Li X, Liu Z, Wang W, Bai H, Yao Y, Li S, Wu A, Sai K, Li G, Yao K, Wei X, Liu X, Zhang Z, Dai Y, Lv S, Wang L, Lin Z, Dong J, Xu G, Ma X, Zhang W, Zhang C, Chen B, You G, Wang Y, Wang Y, Bao Z, Yang P, Fan X, Liu X, Zhao Z, Wang Z, Li Y, Wang Z, Li G, Fang S, Li L, Liu Y, Liu S, Shan X, Liu Y, Chai R, Hu H, Chen J, Yan W, Cai J, Wang H, Chen L, Yang Y, Wang Y, Han L, and Wang Q
- Subjects
- Adult, Antineoplastic Combined Chemotherapy Protocols therapeutic use, Biomarkers, Tumor analysis, Biomarkers, Tumor genetics, Brain diagnostic imaging, Brain pathology, Brain surgery, Brain Neoplasms diagnosis, Brain Neoplasms genetics, Brain Neoplasms mortality, Chemoradiotherapy, Adjuvant methods, China epidemiology, Dose Fractionation, Radiation, Glioma diagnosis, Glioma genetics, Glioma mortality, Humans, Magnetic Resonance Imaging, Medical Oncology organization & administration, Medical Oncology standards, Mutation, Neoplasm Grading, Neurology organization & administration, Neurology standards, Neurosurgical Procedures methods, Progression-Free Survival, Radiotherapy Planning, Computer-Assisted, Societies, Medical standards, Tomography, X-Ray Computed, Brain Neoplasms therapy, Chemoradiotherapy, Adjuvant standards, Glioma therapy, Neurosurgical Procedures standards
- Abstract
To follow the revision of the fourth edition of WHO classification and the recent progress on the management of diffuse gliomas, the joint guideline committee of Chinese Glioma Cooperative Group (CGCG), Society for Neuro-Oncology of China (SNO-China) and Chinese Brain Cancer Association (CBCA) updated the clinical practice guideline. It provides recommendations for diagnostic and management decisions, and for limiting unnecessary treatments and cost. The recommendations focus on molecular and pathological diagnostics, and the main treatment modalities of surgery, radiotherapy, and chemotherapy. In this guideline, we also integrated the results of some clinical trials of immune therapies and target therapies, which we think are ongoing future directions. The guideline should serve as an application for all professionals involved in the management of patients with adult diffuse glioma and also a source of knowledge for insurance companies and other institutions involved in the cost regulation of cancer care in China and other countries., (Copyright © 2020 Elsevier B.V. All rights reserved.)
- Published
- 2021
- Full Text
- View/download PDF
16. Particle radiation therapy in the management of malignant glioma: Early experience at the Shanghai Proton and Heavy Ion Center.
- Author
-
Kong L, Wu J, Gao J, Qiu X, Yang J, Hu J, Hu W, Mao Y, and Lu JJ
- Subjects
- Adult, Aged, Antineoplastic Agents, Alkylating therapeutic use, DNA Modification Methylases metabolism, DNA Repair Enzymes metabolism, Dose Fractionation, Radiation, Female, Glioblastoma drug therapy, Glioblastoma mortality, Glioblastoma pathology, Glioblastoma radiotherapy, Glioma drug therapy, Glioma pathology, Heavy Ion Radiotherapy adverse effects, Humans, Male, Middle Aged, Proton Therapy adverse effects, Temozolomide therapeutic use, Treatment Outcome, Tumor Suppressor Proteins metabolism, Young Adult, Glioma mortality, Glioma radiotherapy, Heavy Ion Radiotherapy methods, Proton Therapy methods
- Abstract
Background: The objective of this study was to evaluate the outcomes of patients with high-grade glioma who received treatment with particle radiotherapy., Methods: Between June 2015 and October 2018, 50 consecutive and nonselected patients with glioblastoma multiforme (n = 34) or anaplastic glioma (n = 16) were treated at the Shanghai Proton and Heavy Ion Center. Twenty-four patients received proton radiotherapy (at a dose of 60 gray-equivalents in 30 daily fractions), and 26 patients received proton radiotherapy plus a carbon-ion radiotherapy (CIRT) boost in various dose-escalating schemes. All patients received temozolomide because of their age or their O-6-methylguanine-DNA methyltransferase (MGMT) promoter methylation status. Progression-free survival (PFS) and overall survival (OS) rates, as well as treatment-induced toxicities, were analyzed., Results: At a median follow-up of 14.3 months (range, 4.8-39.6 months), the 12-month and 18-month OS rates were 87.8% (95% CI, 77.6%-98.0%) and 72.8% (95% CI, 56.7%-88.9%), respectively, and the 12-month and 18-month PFS rates were 74.2% (95% CI, 60.9%-87.5%) and 59.8% (95% CI, 43.1%-76.5%), respectively. Univariate analyses revealed that age (>50 vs ≤50 years), World Health Organization grade (3 vs 4), and Karnofsky performance status (>80 vs ≤80) were significant prognosticators for OS, and IDH mutation and World Health Organization grade were significant for predicting PFS. Furthermore, MGMT promoter methylation, performance status, and age showed a trend toward predicting PFS. No significant predictive factors for PFS or OS were identified in multivariate analyses. Twenty-nine patients experienced grade 1 treatment-related acute adverse effects, and 11 developed grade 1 (n = 6) or grade 2 (n = 5) late adverse effect of radiation-induced brain necrosis. No grade 3, 4, or 5 toxicities were observed., Conclusions: Particle radiotherapy produced 18-month OS and PFS rates of 72.8% and 59.8%, respectively, with acceptable adverse effects in patients with high-grade glioma. Particle radiotherapy at a dose ≥60 gray-equivalents appears to be safe and potentially effective., (© 2020 The Authors. Cancer published by Wiley Periodicals, Inc. on behalf of American Cancer Society.)
- Published
- 2020
- Full Text
- View/download PDF
17. Two novel genetic variants in the STK38L and RAB27A genes are associated with glioma susceptibility.
- Author
-
Chen H, Chen G, Li G, Zhang S, Chen H, Chen Y, Duggan D, Hu Z, Chen J, Zhao Y, Zhao Y, Huang H, Zheng SL, Trent JM, Yu L, Jiang D, Mo Z, Wang H, Mou Y, Jiang T, Mao Y, Xu J, and Lu D
- Subjects
- Brain Neoplasms ethnology, Case-Control Studies, China ethnology, Europe ethnology, Genetic Predisposition to Disease, Genome-Wide Association Study, Glioma ethnology, Humans, Male, Brain Neoplasms genetics, Glioma genetics, Polymorphism, Single Nucleotide, Protein Serine-Threonine Kinases genetics, rab27 GTP-Binding Proteins genetics
- Abstract
Glioma is the most common malignant primary brain tumors with poor prognosis. Genome wide association studies (GWAS) of glioma in populations with Western European ancestry were completed in the US and UK. However, our previous results strongly suggest the genetic heterogeneity could be important in glioma risk. To systematically investigate glioma risk-associated variants in Chinese population, we performed a multistage GWAS of glioma in the Han Chinese population, with a total of 3,097 glioma cases and 4,362 controls. In addition to confirming two associations reported in other ancestry groups, this study identified one new risk-associated locus for glioma on chromosome 12p11.23 (rs10842893, p
meta = 2.33x10-12, STK38L) as well as a promising association at 15q15-21.1 (rs4774756, pmeta = 6.12x10-8, RAB27A) in 3,097 glioma cases and 4,362 controls. Our findings demonstrate two novel association between the glioma risk region marked by variant rs10842893 and rs4774756) and glioma risk. These findings may advance the understanding of genetic susceptibility to glioma., (© 2019 UICC.)- Published
- 2019
- Full Text
- View/download PDF
18. Surface-Enhanced Resonance Raman Scattering-Guided Brain Tumor Surgery Showing Prognostic Benefit in Rat Models.
- Author
-
Han L, Duan W, Li X, Wang C, Jin Z, Zhai Y, Cao C, Chen L, Xu W, Liu Y, Bi YY, Feng J, Mao Y, Yue Q, Zhang XY, and Li C
- Subjects
- Animals, Brain Neoplasms diagnostic imaging, Brain Neoplasms pathology, Cell Line, Tumor, Disease Models, Animal, Glioma diagnostic imaging, Glioma pathology, Gold chemistry, Indoles chemistry, Magnetic Resonance Imaging, Male, Mice, Mice, Nude, Nanostructures chemistry, Neoplasm Recurrence, Local, Prognosis, Rats, Rats, Sprague-Dawley, Surgery, Computer-Assisted, Transplantation, Heterologous, Transplantation, Homologous, Brain Neoplasms surgery, Glioma surgery, Spectrum Analysis, Raman methods
- Abstract
Glioma is the most frequent form of malignant brain tumors. Surgical debulking is a major strategy for glioma treatment. However, there is a great challenge for the neurosurgeons to intraoperatively identify the true margins of glioma because of its infiltrative nature. Tumor residues or microscopic satellite foci left in the resection bed are the main reasons leading to early recurrence as well as poor prognosis. In this study, a surface-enhanced resonance Raman scattering (SERRS) probe was developed to intraoperatively guide glioma resection. In this probe, molecular reporters with absorptive maxima at the near-infrared wavelength range were covalently functionalized on the surface of gold nanostars. This SERRS probe demonstrated an ultrahigh sensitivity with a detection limit of 5.0 pM in aqueous solution. By the development of glioma xenografts in a mouse dorsal skin window chamber, extravasation of this probe from leaky tumor vasculature as functions of time and distance to tumor boundary was investigated. Importantly, the invasive margin of the tumor xenograft was demarcated by this probe with a high signal-to-background ratio. Preoperative magnetic resonance imaging (MRI) first defined the position of orthotopic glioma xenografts in the brain of rat models, and the craniotomy plan was designed. The brain tumor was then excised intraoperatively step-by-step with the assistance of a handheld Raman scanner till the Raman signals of the probe completely disappeared in the resection bed. Notably, longitudinal MRI showed that SERRS-guided surgery significantly reduced the tumor recurrence rate and improved the overall survival of rat models compared with the white light-guided surgery. Overall, this work demonstrates the prognostic benefit of SERRS-guided glioma surgery in animal models. Because delineation of tumor-invasive margins is a common challenge faced by the surgeons, this SERRS probe with a picomolar detection limit holds the promise in improving the surgical outcome of different types of infiltrated tumors.
- Published
- 2019
- Full Text
- View/download PDF
19. Rapid diagnosis of IDH1-mutated gliomas by 2-HG detection with gas chromatography mass spectrometry.
- Author
-
Xu H, Xia YK, Li CJ, Zhang JY, Liu Y, Yi W, Qin ZY, Chen L, Shi ZF, Quan K, Yang ZX, Guan KL, Xiong Y, Ng HK, Ye D, Hua W, and Mao Y
- Subjects
- Adult, Humans, Immunohistochemistry, Middle Aged, Mutation genetics, Brain Neoplasms chemistry, Brain Neoplasms diagnosis, Brain Neoplasms genetics, Gas Chromatography-Mass Spectrometry methods, Glioma chemistry, Glioma diagnosis, Glioma genetics, Glutarates analysis, Isocitrate Dehydrogenase genetics
- Abstract
The metabolic genes encoding isocitrate dehydrogenase (IDH1, 2) are frequently mutated in gliomas. Mutation of IDH defines a distinct subtype of glioma and predicts therapeutic response. IDH mutation has a remarkable neomorphic activity of converting α-ketoglutarate (α-KG) to 2-hydroxyglutarate (2-HG), which is now commonly referred to as an oncometabolite and biomarker for gliomas. PCR-sequencing (n = 220), immunohistochemistry staining (IHC, n = 220), and gas chromatography mass spectrometry (GC-MS, n = 87) were applied to identify IDH mutation in gliomas, and the sensitivity and specificity of these strategies were compared. PCR-sequencing and IHC staining are reliable for retrospective assessment of IDH1 mutation in gliomas, but both methods usually take 1-2 days, which hinders their application for rapid diagnosis. GC-MS-based methods can detect 2-HG qualitatively and quantitatively, offering information on the IDH1 mutation status in gliomas with the sensitivity and specificity being 100%. Further optimization of the GC-MS based methodology (so called as the mini-column method) enabled us to determine 2-HG within 40 min in glioma samples without complex or time-consuming preparation. Most importantly, the ratio of 2-HG/glutamic acid was shown to be a reliable parameter for determination of mutation status. The mini-column method enables rapid identification of 2-HG, providing a promising strategy for intraoperative diagnosis of IDH1-mutated gliomas in the future.
- Published
- 2019
- Full Text
- View/download PDF
20. Point-of-Care Tissue Analysis Using Miniature Mass Spectrometer.
- Author
-
Zou R, Cao W, Chong L, Hua W, Xu H, Mao Y, Page J, Shi R, Xia Y, Hu TY, Zhang W, and Ouyang Z
- Subjects
- Animals, Brain, Breast, Glioma diagnosis, Humans, Kidney, Liver, Male, Mass Spectrometry, Rats, Rats, Sprague-Dawley, Fatty Acids analysis, Glioma chemistry, Glutarates analysis, Lipids analysis, Point-of-Care Testing
- Abstract
The combination of direct sampling ionization and miniature mass spectrometer presents a promising technical pathway of point-of-care analysis in clinical applications. In this work, a miniature mass spectrometry system was used for analysis of tissue samples. Direct tissue sampling coupled with extraction spray ionization was used with a home-built miniature mass spectrometer, Mini 12. Lipid species in tissue samples were well profiled in rat brain, kidney, and liver in a couple of minutes. By incorporating a photochemical (Paternò-Büchi) reaction, fast identification of lipid C═C location was realized. Relative quantitation of the lipid C═C isomer was performed by calculating the intensity ratio C═C diagnostic product ions, by which FA 18:1 (Δ9)/FA 18:1 (Δ11) was found to change significantly in mouse cancerous breast tissue samples. Accumulation of 2-hydroxylglutarate in human glioma samples, not in normal brains, can also be easily identified for rapid diagnosis.
- Published
- 2019
- Full Text
- View/download PDF
21. Image-guided chemotherapy with specifically tuned blood brain barrier permeability in glioma margins.
- Author
-
Gao X, Yue Q, Liu Y, Fan D, Fan K, Li S, Qian J, Han L, Fang F, Xu F, Geng D, Chen L, Zhou X, Mao Y, and Li C
- Subjects
- Adenosine A2 Receptor Agonists administration & dosage, Adenosine A2 Receptor Agonists therapeutic use, Adult, Aged, Animals, Antineoplastic Agents therapeutic use, Blood-Brain Barrier diagnostic imaging, Brain Neoplasms diagnostic imaging, Capillary Permeability, Female, Glioma diagnostic imaging, Humans, Integrin beta3 metabolism, Magnetic Resonance Imaging methods, Male, Margins of Excision, Mice, Middle Aged, Nanoparticles therapeutic use, Purines administration & dosage, Pyrazoles administration & dosage, Single Photon Emission Computed Tomography Computed Tomography, Tight Junctions drug effects, Tight Junctions metabolism, Zonula Occludens-1 Protein metabolism, Antineoplastic Agents administration & dosage, Blood-Brain Barrier metabolism, Brain Neoplasms drug therapy, Drug Delivery Systems, Drug Therapy, Computer-Assisted, Glioma drug therapy, Nanoparticles administration & dosage
- Abstract
Blood-brain barrier (BBB) disruption is frequently observed in the glioma region. However, the tumor uptake of drugs is still too low to meet the threshold of therapeutic purpose. Method: A tumor vasculature-targeted nanoagonist was developed. Glioma targeting specificity of the nanoagonist was evaluated by in vivo optical imaging. BBB permeability at the glioma margin was quantitatively measured by dynamic contrast enhanced magnetic resonance imaging (DCE-MRI). Single-photon emission computed tomography imaging/computed tomography (SPECT/CT) quantitatively determined the glioma uptake of the radiolabeled model drug. T2-weighted MRI monitored the tumor volume. Results: Immunostaining studies demonstrated that the BBB remained partially intact in the invasive margin of patients' gliomas regardless of their malignancies. DCE-MRI showed that vascular permeability in the glioma margin reached its maximum at 45 min post nanoagonist administration. In vivo optical imaging indicated the high glioma targeting specificity of the nanoagonist. SPECT/CT showed the significantly enhanced glioma uptake of the model drug after pre-treatment with the nanoagonist. Image-guided paclitaxel injection after nanoagonist-mediated BBB modulation more efficiently attenuated tumor growth and extended survival than in animal models treated with paclitaxel or temozolomide alone. Conclusion: Thus, image-guided drug delivery following BBB permeability modulation holds promise to enhance the efficacy of chemotherapeutics to glioma., Competing Interests: Competing Interests: The authors have declared that no competing interest exists.
- Published
- 2018
- Full Text
- View/download PDF
22. Anatomical location differences between mutated and wild-type isocitrate dehydrogenase 1 in low-grade gliomas.
- Author
-
Yu J, Shi Z, Ji C, Lian Y, Wang Y, Chen L, and Mao Y
- Subjects
- Adult, Brain Neoplasms diagnostic imaging, Brain Neoplasms genetics, Female, Glioma diagnostic imaging, Glioma genetics, Humans, Magnetic Resonance Imaging, Male, Middle Aged, Mutation, Neoplasm Grading, Brain Neoplasms pathology, Glioma pathology, Isocitrate Dehydrogenase genetics
- Abstract
Anatomical location of gliomas has been considered as a factor implicating the contributions of a specific precursor cells during the tumor growth. Isocitrate dehydrogenase 1 (IDH1) is a pathognomonic biomarker with a significant impact on the development of gliomas and remarkable prognostic effect. The correlation between anatomical location of tumor and IDH1 states for low-grade gliomas was analyzed quantitatively in this study. Ninety-two patients diagnosed of low-grade glioma pathologically were recruited in this study, including 65 patients with IDH1-mutated glioma and 27 patients with wide-type IDH1. A convolutional neural network was designed to segment the tumor from three-dimensional magnetic resonance imaging images. Voxel-based lesion symptom mapping was then employed to study the tumor location distribution differences between gliomas with mutated and wild-type IDH1. In order to characterize the location differences quantitatively, the Automated Anatomical Labeling Atlas was used to partition the standard brain atlas into 116 anatomical volumes of interests (AVOIs). The percentages of tumors with different IDH1 states in 116 AVOIs were calculated and compared. Support vector machine and AdaBoost algorithms were used to estimate the IDH1 status based on the 116 location features of each patient. Experimental results proved that the quantitative tumor location measurement could be a very important group of imaging features in biomarker estimation based on radiomics analysis of glioma.
- Published
- 2017
- Full Text
- View/download PDF
23. Therapeutic and Prognostic Implications of BRAF V600E in Pediatric Low-Grade Gliomas.
- Author
-
Lassaletta A, Zapotocky M, Mistry M, Ramaswamy V, Honnorat M, Krishnatry R, Guerreiro Stucklin A, Zhukova N, Arnoldo A, Ryall S, Ling C, McKeown T, Loukides J, Cruz O, de Torres C, Ho CY, Packer RJ, Tatevossian R, Qaddoumi I, Harreld JH, Dalton JD, Mulcahy-Levy J, Foreman N, Karajannis MA, Wang S, Snuderl M, Nageswara Rao A, Giannini C, Kieran M, Ligon KL, Garre ML, Nozza P, Mascelli S, Raso A, Mueller S, Nicolaides T, Silva K, Perbet R, Vasiljevic A, Faure Conter C, Frappaz D, Leary S, Crane C, Chan A, Ng HK, Shi ZF, Mao Y, Finch E, Eisenstat D, Wilson B, Carret AS, Hauser P, Sumerauer D, Krskova L, Larouche V, Fleming A, Zelcer S, Jabado N, Rutka JT, Dirks P, Taylor MD, Chen S, Bartels U, Huang A, Ellison DW, Bouffet E, Hawkins C, and Tabori U
- Subjects
- Adolescent, Brain Neoplasms genetics, Brain Neoplasms pathology, Brain Neoplasms therapy, Brain Stem Neoplasms enzymology, Brain Stem Neoplasms genetics, Brain Stem Neoplasms pathology, Brain Stem Neoplasms therapy, Child, Child, Preschool, Cohort Studies, Diencephalon enzymology, Diencephalon pathology, Female, Glioma genetics, Glioma pathology, Glioma therapy, Humans, Infant, Male, Mutation, Neoplasm Grading, Prognosis, Brain Neoplasms enzymology, Glioma enzymology, Proto-Oncogene Proteins B-raf genetics
- Abstract
Purpose BRAF V600E is a potentially highly targetable mutation detected in a subset of pediatric low-grade gliomas (PLGGs). Its biologic and clinical effect within this diverse group of tumors remains unknown. Patients and Methods A combined clinical and genetic institutional study of patients with PLGGs with long-term follow-up was performed (N = 510). Clinical and treatment data of patients with BRAF V600E mutated PLGG (n = 99) were compared with a large international independent cohort of patients with BRAF V600E mutated-PLGG (n = 180). Results BRAF V600E mutation was detected in 69 of 405 patients (17%) with PLGG across a broad spectrum of histologies and sites, including midline locations, which are not often routinely biopsied in clinical practice. Patients with BRAF V600E PLGG exhibited poor outcomes after chemotherapy and radiation therapies that resulted in a 10-year progression-free survival of 27% (95% CI, 12.1% to 41.9%) and 60.2% (95% CI, 53.3% to 67.1%) for BRAF V600E and wild-type PLGG, respectively ( P < .001). Additional multivariable clinical and molecular stratification revealed that the extent of resection and CDKN2A deletion contributed independently to poor outcome in BRAF V600E PLGG. A similar independent role for CDKN2A and resection on outcome were observed in the independent cohort. Quantitative imaging analysis revealed progressive disease and a lack of response to conventional chemotherapy in most patients with BRAF V600E PLGG. Conclusion BRAF V600E PLGG constitutes a distinct entity with poor prognosis when treated with current adjuvant therapy.
- Published
- 2017
- Full Text
- View/download PDF
24. Noninvasive IDH1 mutation estimation based on a quantitative radiomics approach for grade II glioma.
- Author
-
Yu J, Shi Z, Lian Y, Li Z, Liu T, Gao Y, Wang Y, Chen L, and Mao Y
- Subjects
- Adolescent, Adult, Aged, Biomarkers, Tumor genetics, Brain Neoplasms diagnostic imaging, Brain Neoplasms pathology, Child, Child, Preschool, Cohort Studies, Female, Glioma diagnostic imaging, Glioma pathology, Humans, Image Interpretation, Computer-Assisted methods, Infant, Infant, Newborn, Magnetic Resonance Imaging methods, Male, Middle Aged, Neoplasm Grading, Neoplasm Proteins genetics, Prognosis, ROC Curve, Retrospective Studies, Sensitivity and Specificity, Young Adult, Brain Neoplasms genetics, Glioma genetics, Isocitrate Dehydrogenase genetics, Mutation
- Abstract
Objective: The status of isocitrate dehydrogenase 1 (IDH1) is highly correlated with the development, treatment and prognosis of glioma. We explored a noninvasive method to reveal IDH1 status by using a quantitative radiomics approach for grade II glioma., Methods: A primary cohort consisting of 110 patients pathologically diagnosed with grade II glioma was retrospectively studied. The radiomics method developed in this paper includes image segmentation, high-throughput feature extraction, radiomics sequencing, feature selection and classification. Using the leave-one-out cross-validation (LOOCV) method, the classification result was compared with the real IDH1 situation from Sanger sequencing. Another independent validation cohort containing 30 patients was utilised to further test the method., Results: A total of 671 high-throughput features were extracted and quantized. 110 features were selected by improved genetic algorithm. In LOOCV, the noninvasive IDH1 status estimation based on the proposed approach presented an estimation accuracy of 0.80, sensitivity of 0.83 and specificity of 0.74. Area under the receiver operating characteristic curve reached 0.86. Further validation on the independent cohort of 30 patients produced similar results., Conclusions: Radiomics is a potentially useful approach for estimating IDH1 mutation status noninvasively using conventional T2-FLAIR MRI images. The estimation accuracy could potentially be improved by using multiple imaging modalities., Key Points: • Noninvasive IDH1 status estimation can be obtained with a radiomics approach. • Automatic and quantitative processes were established for noninvasive biomarker estimation. • High-throughput MRI features are highly correlated to IDH1 states. • Area under the ROC curve of the proposed estimation method reached 0.86.
- Published
- 2017
- Full Text
- View/download PDF
25. Low-Grade Glioma Segmentation Based on CNN with Fully Connected CRF.
- Author
-
Li Z, Wang Y, Yu J, Shi Z, Guo Y, Chen L, and Mao Y
- Subjects
- Female, Humans, Imaging, Three-Dimensional, Magnetic Resonance Imaging, Male, Brain Neoplasms diagnostic imaging, Glioma diagnostic imaging, Image Processing, Computer-Assisted methods, Neural Networks, Computer
- Abstract
This work proposed a novel automatic three-dimensional (3D) magnetic resonance imaging (MRI) segmentation method which would be widely used in the clinical diagnosis of the most common and aggressive brain tumor, namely, glioma. The method combined a multipathway convolutional neural network (CNN) and fully connected conditional random field (CRF). Firstly, 3D information was introduced into the CNN which makes more accurate recognition of glioma with low contrast. Then, fully connected CRF was added as a postprocessing step which purposed more delicate delineation of glioma boundary. The method was applied to T2flair MRI images of 160 low-grade glioma patients. With 59 cases of data training and manual segmentation as the ground truth, the Dice similarity coefficient (DSC) of our method was 0.85 for the test set of 101 MRI images. The results of our method were better than those of another state-of-the-art CNN method, which gained the DSC of 0.76 for the same dataset. It proved that our method could produce better results for the segmentation of low-grade gliomas.
- Published
- 2017
- Full Text
- View/download PDF
26. TP53 and Histone H3.3 Mutations in Triple-Negative Lower-Grade Gliomas.
- Author
-
Chan AK, Mao Y, and Ng HK
- Subjects
- Brain Neoplasms genetics, Humans, Mutation, Tumor Suppressor Protein p53 genetics, Glioma genetics, Histones genetics
- Published
- 2016
- Full Text
- View/download PDF
27. CGCG clinical practice guidelines for the management of adult diffuse gliomas.
- Author
-
Jiang T, Mao Y, Ma W, Mao Q, You Y, Yang X, Jiang C, Kang C, Li X, Chen L, Qiu X, Wang W, Li W, Yao Y, Li S, Li S, Wu A, Sai K, Bai H, Li G, Chen B, Yao K, Wei X, Liu X, Zhang Z, Dai Y, Lv S, Wang L, Lin Z, Dong J, Xu G, Ma X, Cai J, Zhang W, Wang H, Chen L, Zhang C, Yang P, Yan W, Liu Z, Hu H, Chen J, Liu Y, Yang Y, Wang Z, Wang Z, Wang Y, You G, Han L, Bao Z, Liu Y, Wang Y, Fan X, Liu S, Liu X, Wang Y, and Wang Q
- Subjects
- Adult, China, Clinical Trials as Topic, Evidence-Based Medicine, Glioma pathology, Humans, Disease Management, Glioma therapy, Practice Guidelines as Topic
- Abstract
The Chinese Glioma Cooperative Group (CGCG) Guideline Panel for adult diffuse gliomas provided recommendations for diagnostic and therapeutic procedures. The Panel covered all fields of expertise in neuro-oncology, i.e. neurosurgeons, neurologists, neuropathologists, neuroradiologists, radiation and medical oncologists and clinical trial experts. The task made clearer and more transparent choices about outcomes considered most relevant through searching the references considered most relevant and evaluating their value. The scientific evidence of papers collected from the literature was evaluated and graded based on the Oxford Centre for Evidence-based Medicine Levels of Evidence and recommendations were given accordingly. The recommendations will provide a framework and assurance for the strategy of diagnostic and therapeutic measures to reduce complications from unnecessary treatment and cost. The guideline should serve as an application for all professionals involved in the management of patients with adult diffuse glioma and also as a source of knowledge for insurance companies and other institutions involved in the cost regulation of cancer care in China., (Copyright © 2016 The Authors. Published by Elsevier Ireland Ltd.. All rights reserved.)
- Published
- 2016
- Full Text
- View/download PDF
28. Abscisic-acid-induced cellular apoptosis and differentiation in glioma via the retinoid acid signaling pathway.
- Author
-
Zhou N, Yao Y, Ye H, Zhu W, Chen L, and Mao Y
- Subjects
- Abscisic Acid pharmacology, Adult, Aged, Apoptosis drug effects, Blotting, Western, Cell Differentiation physiology, Female, Flow Cytometry, Glioma metabolism, Humans, Immunohistochemistry, Male, Middle Aged, RNA, Small Interfering, Radioimmunoassay, Real-Time Polymerase Chain Reaction, Signal Transduction drug effects, Transfection, Tretinoin pharmacology, Young Adult, Abscisic Acid metabolism, Apoptosis physiology, Glioma pathology, Signal Transduction physiology, Tretinoin metabolism
- Abstract
Retinoid acid (RA) plays critical roles in regulating differentiation and apoptosis in a variety of cancer cells. Abscisic acid (ABA) and RA are direct derivatives of carotenoids and share structural similarities. Here we proposed that ABA may also play a role in cellular differentiation and apoptosis by sharing a similar signaling pathway with RA that may be involved in glioma pathogenesis. We reported for the first time that the ABA levels were twofold higher in low-grade gliomas compared with high-grade gliomas. In glioma tissues, there was a positive correlation between the ABA levels and the transcription of cellular retinoic acid-binding protein 2 (CRABP2) and a negative correlation between the ABA levels and transcription of fatty acid-binding protein 5 (FABP5). ABA treatment induced a significant increase in the expression of CRABP2 and a decrease in the expression of peroxisome proliferator-activated receptor (PPAR) in glioblastoma cells. Remarkably, both cellular apoptosis and differentiation were increased in the glioblastoma cells after ABA treatment. ABA-induced cellular apoptosis and differentiation were significantly reduced by selectively silencing RAR-α, while RAR-α overexpression exaggerated the ABA-induced effects. These results suggest that ABA may play a role in the pathogenesis of glioma by promoting cellular apoptosis and differentiation through the RA signaling pathway., (© 2015 UICC.)
- Published
- 2016
- Full Text
- View/download PDF
29. The clinical utility of multimodal MR image-guided needle biopsy in cerebral gliomas.
- Author
-
Yao C, Lv S, Chen H, Tang W, Guo J, Zhuang D, Chrisochoides N, Wu J, Mao Y, and Zhou L
- Subjects
- Adolescent, Adult, Brain Neoplasms diagnosis, Brain Neoplasms surgery, Contrast Media, Diffusion Magnetic Resonance Imaging, Female, Frozen Sections, Glioblastoma diagnosis, Glioblastoma pathology, Glioblastoma surgery, Glioma diagnosis, Glioma surgery, Humans, Male, Middle Aged, Observer Variation, Retrospective Studies, Single-Blind Method, Stereotaxic Techniques, Young Adult, Biopsy, Needle methods, Brain Neoplasms pathology, Glioma pathology, Image-Guided Biopsy, Magnetic Resonance Imaging methods, Magnetic Resonance Spectroscopy methods, Multimodal Imaging, Neuroimaging methods
- Abstract
Purpose: Our aim was to evaluate the diagnostic value of multimodal Magnetic Resonance (MR) Image in the stereotactic biopsy of cerebral gliomas, and investigate its implications., Materials and Methods: Twenty-four patients with cerebral gliomas underwent (1)H Magnetic Resonance Spectroscopy ((1)H-MRS)- and intraoperative Magnetic Resonance Imaging (iMRI)-supported stereotactic biopsy, and 23 patients underwent only the preoperative MRI-guided biopsy. The diagnostic yield, morbidity and mortality rates were analyzed. In addition, 20 patients underwent subsequent tumor resection, thus the diagnostic accuracy of the biopsy was further evaluated., Results: The diagnostic accuracies of biopsies evaluated by tumor resection in the trial groups were better than control groups (92.3% and 42.9%, respectively, p = 0.031). The diagnostic yield in the trial groups was better than the control groups, but the difference was not statistically significant (100% and 82.6%, respectively, p = 0.05). The morbidity and mortality rates were similar in both groups., Conclusions: Multimodal MR image-guided glioma biopsy is practical and valuable. This technique can increase the diagnostic accuracy in the stereotactic biopsy of cerebral gliomas. Besides, it is likely to increase the diagnostic yield but requires further validation.
- Published
- 2016
- Full Text
- View/download PDF
30. TRIM28 as an independent prognostic marker plays critical roles in glioma progression.
- Author
-
Qi ZX, Cai JJ, Chen LC, Yue Q, Gong Y, Yao Y, and Mao Y
- Subjects
- Adult, Animals, Brain metabolism, Brain pathology, Brain Neoplasms mortality, Cell Cycle Checkpoints genetics, Cell Line, Tumor, Cyclin-Dependent Kinase Inhibitor p21 genetics, Cyclin-Dependent Kinase Inhibitor p21 metabolism, Disease Progression, Female, Glioma genetics, Glioma mortality, Humans, Male, Mice, Mice, Nude, Middle Aged, RNA, Small Interfering genetics, RNA, Small Interfering metabolism, Repressor Proteins genetics, Survival Analysis, Time Factors, Tripartite Motif-Containing Protein 28, Xenograft Model Antitumor Assays, Brain Neoplasms diagnosis, Gene Expression Regulation genetics, Glioma diagnosis, Repressor Proteins metabolism
- Abstract
Tripartite motif (TRIM) proteins are involved in tumorigenesis. Here, we examined the expression, biological function, and clinical significance of tripartite motif containing 28 (TRIM28) in glioma, a locally aggressive brain tumor. First, TRIM28 expression was significantly higher in glioma (n = 138) than in non-glioma controls (n = 6). TRIM28 expression was positively correlated with tumor malignancy, and associated with poor overall survival (OS) and progression-free survival (PFS). Notably, TRIM28 expression was negatively correlated with p21 expression in patients with glioblastoma multiforme (GBM). A multivariate analysis that included relevant measures indicated that high TRIM28 expression is an independent prognostic factor for poor OS and PFS in GBM patients. In experiments with cultured glioma cells, down-regulating TRIM28 with shRNA increased p21 expression, and induced cell cycle arrest at the G1 phase. In a xenograft model, down-regulating TRIM28 suppressed tumor growth. These results indicate that over-expression of TRIM28 is associated with poor outcome in glioma patients.
- Published
- 2016
- Full Text
- View/download PDF
31. TERT promoter mutations contribute to IDH mutations in predicting differential responses to adjuvant therapies in WHO grade II and III diffuse gliomas.
- Author
-
Zhang ZY, Chan AK, Ding XJ, Qin ZY, Hong CS, Chen LC, Zhang X, Zhao FP, Wang Y, Wang Y, Zhou LF, Zhuang Z, Ng HK, Yan H, Yao Y, and Mao Y
- Subjects
- Adult, Brain Neoplasms pathology, Brain Neoplasms therapy, Chemoradiotherapy, Adjuvant, Cohort Studies, Female, Glioma pathology, Glioma therapy, Humans, Kaplan-Meier Estimate, Male, Middle Aged, Multivariate Analysis, Neoplasm Grading, Prognosis, Treatment Outcome, Brain Neoplasms genetics, Glioma genetics, Isocitrate Dehydrogenase genetics, Mutation, Promoter Regions, Genetic genetics, Telomerase genetics
- Abstract
IDH mutations frequently occur in WHO grade II and III diffuse gliomas and have favorable prognosis compared to wild-type tumors. However, whether IDH mutations in WHO grade II and II diffuse gliomas predict enhanced sensitivity to adjuvant radiation (RT) or chemotherapy (CHT) is still being debated. Recent studies have identified recurrent mutations in the promoter region of telomerase reverse transcriptase (TERT) in gliomas. We previously demonstrated that TERT promoter mutations may be promising biomarkers in glioma survival prognostication when combined with IDH mutations. This study analyzed IDH and TERT promoter mutations in 295 WHO grade II and III diffuse gliomas treated with or without adjuvant therapies to explore their impact on the sensitivity of tumors to genotoxic therapies. IDH mutations were found in 216 (73.2%) patients and TERT promoter mutations were found in 112 (38%) patients. In multivariate analysis, IDH mutations (p < 0.001) were independent prognostic factors for PFS and OS in patients receiving genotoxic therapies while TERT promoter mutations were not. In univariate analysis, IDH and TERT promoter mutations were not significant prognostic factors in patients who did not receive genotoxic therapies. Adjuvant RT and CHT were factors independently impacting PFS (RT p = 0.001, CHT p = 0.026) in IDH mutated WHO grade II and III diffuse gliomas but not in IDH wild-type group. Univariate and multivariate analyses demonstrated TERT promoter mutations further stratified IDH wild-type WHO grade II and III diffuse gliomas into two subgroups with different responses to genotoxic therapies. Adjuvant RT and CHT were significant parameters influencing PFS in the IDH wt/TERT mut subgroup (RT p = 0.015, CHT p = 0.015) but not in the IDH wt/TERT wt subgroup. Our data demonstrated that IDH mutated WHO grade II and III diffuse gliomas had better PFS and OS than their IDH wild-type counterparts when genotoxic therapies were administered after surgery. Importantly, we also found that TERT promoter mutations further stratify IDH wild-type WHO grade II and III diffuse gliomas into two subgroups with different responses to adjuvant therapies. Taken together, TERT promoter mutations may predict enhanced sensitivity to genotoxic therapies in IDH wild-type WHO grade II and III diffuse gliomas and may justify intensified treatment in this subgroup.
- Published
- 2015
- Full Text
- View/download PDF
32. Establishment and maintenance of a standardized glioma tissue bank: Huashan experience.
- Author
-
Aibaidula A, Lu JF, Wu JS, Zou HJ, Chen H, Wang YQ, Qin ZY, Yao Y, Gong Y, Che XM, Zhong P, Li SQ, Bao WM, Mao Y, and Zhou LF
- Subjects
- Adolescent, Adult, Aged, Aged, 80 and over, Child, Child, Preschool, China, Databases, Factual standards, Female, Glioma surgery, Humans, Infant, Male, Middle Aged, Specimen Handling, Translational Research, Biomedical standards, Young Adult, Biological Specimen Banks standards, Biomedical Research standards, Glioma pathology
- Abstract
Cerebral glioma is the most common brain tumor as well as one of the top ten malignant tumors in human beings. In spite of the great progress on chemotherapy and radiotherapy as well as the surgery strategies during the past decades, the mortality and morbidity are still high. One of the major challenges is to explore the pathogenesis and invasion of glioma at various "omics" levels (such as proteomics or genomics) and the clinical implications of biomarkers for diagnosis, prognosis or treatment of glioma patients. Establishment of a standardized tissue bank with high quality biospecimens annotated with clinical information is pivotal to the solution of these questions as well as the drug development process and translational research on glioma. Therefore, based on previous experience of tissue banks, standardized protocols for sample collection and storage were developed. We also developed two systems for glioma patient and sample management, a local database for medical records and a local image database for medical images. For future set-up of a regional biobank network in Shanghai, we also founded a centralized database for medical records. Hence we established a standardized glioma tissue bank with sufficient clinical data and medical images in Huashan Hospital. By September, 2013, tissues samples from 1,326 cases were collected. Histological diagnosis revealed that 73 % were astrocytic tumors, 17 % were oligodendroglial tumors, 2 % were oligoastrocytic tumors, 4 % were ependymal tumors and 4 % were other central nervous system neoplasms.
- Published
- 2015
- Full Text
- View/download PDF
33. Activation of hypoxia signaling induces phenotypic transformation of glioma cells: implications for bevacizumab antiangiogenic therapy.
- Author
-
Xu H, Rahimpour S, Nesvick CL, Zhang X, Ma J, Zhang M, Zhang G, Wang L, Yang C, Hong CS, Germanwala AV, Elder JB, Ray-Chaudhury A, Yao Y, Gilbert MR, Lonser RR, Heiss JD, Brady RO, Mao Y, Qin J, and Zhuang Z
- Subjects
- Basic Helix-Loop-Helix Transcription Factors metabolism, Cell Hypoxia drug effects, Cell Hypoxia physiology, Cell Line, Tumor, Gene Knockdown Techniques, Humans, Hypoxia-Inducible Factor 1, alpha Subunit metabolism, Microfluidic Analytical Techniques, Neovascularization, Pathologic metabolism, Phenotype, RNA, Small Interfering, Signal Transduction drug effects, Signal Transduction physiology, Angiogenesis Inhibitors pharmacology, Bevacizumab pharmacology, Brain Neoplasms pathology, Cell Transformation, Neoplastic metabolism, Epithelial-Mesenchymal Transition drug effects, Glioma pathology
- Abstract
Glioblastoma (GBM) is the most common and deadly primary brain tumor in adults. Bevacizumab, a humanized monoclonal antibody against vascular endothelial growth factor (VEGF), can attenuate tumor-associated edema and improve patient symptoms but based on magnetic resonance imaging, is associated with non-enhancing tumor progression and possibly gliosarcoma differentiation. To gain insight into these findings, we investigated the role of hypoxia and epithelial-mesenchymal transition (EMT)-associated proteins in GBM. Tumor markers of hypoxia and EMT were upregulated in bevacizumab-treated tumors from GBM patients compared to untreated counterparts. Exposure of glioma cells to 1% oxygen tension increased cell proliferation, expression of EMT-associated proteins and enhanced cell migration in vitro. These phenotypic changes were significantly attenuated by pharmacologic knockdown of hypoxia-inducible Factor 1α (HIF1α) or HIF2α, indicating that HIFs represent a therapeutic target for mesenchymal GBM cells. These findings provide insights into potential development of novel therapeutic targeting of angiogenesis-specific pathways in GBM.
- Published
- 2015
- Full Text
- View/download PDF
34. Genetic variants in N-myc (and STAT) interactor and susceptibility to glioma in a Chinese Han population.
- Author
-
Meng D, Li X, Zhang S, Zhao Y, Song X, Chen Y, Wang S, Mao Y, Chen H, and Lu D
- Subjects
- Adult, Alleles, Case-Control Studies, Female, Genetic Predisposition to Disease, Genotype, Humans, Male, Odds Ratio, Polymorphism, Single Nucleotide, Promoter Regions, Genetic, Risk, Risk Factors, Asian People genetics, Brain Neoplasms genetics, Glioma genetics, Intracellular Signaling Peptides and Proteins genetics
- Abstract
Glioma is one of the most common and lethal brain tumors. N-myc (and STAT) interactor (NMI) gene has been reported in tumorigenesis, and our previous study further showed its implication in glioma progression. To elucidate its involvement in the etiology of glioma, we conducted a case-control study of 875 patients and 1040 controls in a Chinese Han population by genotyping 7 representative single nucleotide polymorphisms (SNPs) in NMI. Allele and genotype frequency distribution of five loci (rs2278089, rs2194492, rs6734376, rs3854012, and rs11730) were significantly different between the cases and controls. Unconditional logistic regression showed that the variant genotypes of rs2278089 [adjusted odds ratio (OR) = 1.57, P = 4.23 × 10(-6)], rs2194492 (adjusted OR = 1.49, P = 1.20 × 10(-4)), and rs6734376 (adjusted OR = 0.06, P = 8.65 × 10(-13)) significantly affected glioma risk compared with the major homozygotes, while the minor homozygotes of rs3854012 (adjusted OR = 0.54, P = 4.64 × 10(-6)) and rs11730 (adjusted OR = 0.60, P = 1.50 × 10(-4)) showed significant protective effects. Further stratified analyses indicated that these associations remained significant in subgroups of low-grade glioma (LGG) and high-grade glioma (HGG). Additionally, haplotype and diplotype analyses showed consistent results. The Bonferroni correction was applied for all these analyses. Moreover, luciferase reporter gene assays revealed enhanced promoter activity of the C risk allele of rs2194492 in several cell lines compared with the G major allele, suggesting its potential function in transcriptional activation of NMI. Taken together, these results revealed that NMI polymorphisms may contribute to genetic susceptibility to glioma.
- Published
- 2015
- Full Text
- View/download PDF
35. Methods of glioma sample processing for molecular diagnosis for the glioma tissue bank project.
- Author
-
Shi ZF, Aibaidula A, Tang QS, Shen YW, Chen H, Wu JS, Qin ZY, Zhu JH, Mao Y, and Zhou LF
- Subjects
- Brain Neoplasms genetics, Brain Neoplasms surgery, DNA, Neoplasm analysis, Glioma genetics, Glioma surgery, Humans, Quality Control, Specimen Handling methods, Brain Neoplasms pathology, Glioma pathology, Neuronavigation methods, Sequence Analysis, DNA methods, Tissue Banks
- Abstract
Genome-wide sequencing in glioma samples provides comprehensive insights into oncogenesis and malignant transformation. Several distinct biomarkers have been proven to have clinical significance and are being widely applied in routine clinical practice. Standard sample processing lays the foundation for successful molecular testing. In this study, we found intraoperative neuronavigation ensured higher tumor purity during sample collection, and an automated device helped improve DNA quality and increased yields. These two technologies are beneficial for glioma tissue bank construction and provide for accurate molecular testing during routine clinical practice.
- Published
- 2015
- Full Text
- View/download PDF
36. Surgically treated incidentally discovered low-grade gliomas are mostly IDH mutated and 1p19q co-deleted with favorable prognosis.
- Author
-
Zhang ZY, Chan AK, Ng HK, Ding XJ, Li YX, Shi ZF, Zhu W, Zhong P, Wang Y, Mao Y, Yao Y, and Zhou LF
- Subjects
- Adult, Brain Neoplasms surgery, Chromosome Deletion, Chromosomes, Human, Pair 1 genetics, Chromosomes, Human, Pair 19 genetics, DNA Mutational Analysis, Female, Glioma surgery, Humans, Immunohistochemistry, In Situ Hybridization, Fluorescence, Incidental Findings, Kaplan-Meier Estimate, Male, Neoplasm Grading, Prognosis, Brain Neoplasms genetics, Brain Neoplasms pathology, Glioma genetics, Glioma pathology, Isocitrate Dehydrogenase genetics, Mutation
- Abstract
Objective: LGGs (low-grade gliomas) are sometimes encountered by chance during radiological examinations. These incidentally discovered LGGs (IDLGGs) were relatively under-studied in the literature. The purpose of current study is to review a cohort of patients with IDLGGs surgically treated in our institution for their clinical and histological aspects and determine their IDH1 and 1p19q status., Methods: All patients with hemispheric LGGs receiving operation in our institution between 2001 and 2004 were reviewed. Clinical, radiological and treatment data of the patients were collected and IDLGGs were retrieved and compared with symptomatic LGGs. Histological review was carried out and formalin-fixed paraffin embedded (FFPE) tissues of IDLGGs were examined for IDH1/IDH2 mutation and 1p/19q codeletion., Results: Twenty three IDLGGs (10.4%) were identified while 196 patients had symptomatic LGGs. The reasons for patients with IDLGGs having radiological examination included trauma (47.8%), dizziness (26.1%), unrelated headache (21.7%), and health checkup (4.4%). Clinically, patients with IDLGGs had higher preoperative KPS (P < 0.001), smaller tumor volume (P = 0.014), lower frequency of eloquent areas involvement (P < 0.001) and higher rate of complete resection (P = 0.037) comparing to those with symptomatic LGGs. Histologically, there is a preponderance of oligodendroglial differentiation with 6 oligodendrogliomas and 11 oligoastrocytomas but there were also 6 astrocytomas. IDH1 mutation and 1p/19q co-deletion were detected in 95.7% (22/23) and 69.6% (16/23) of IDLGGs, respectively. The latter encompassed all but one of the cases of oligodendroglial tumors. Patients with IDLGGs had longer overall survival than those with symptomatic LGGs (P = 0.027)., Conclusions: We conclude that the majority of IDLGGs are IDH1 mutated and are predominantly oligodendroglial tumors. With a median follow-up of 9.3 years to our series, we conclude that patients with IDLGGs had better prognosis than those with symptomatic LGGs. The favorable prognosis of IDLGGs may be accounted by the higher practicability of extensive resection, non-eloquent tumor location and smaller tumor volume. Frequent IDH1 mutation and 1p/19q co-deletion in IDLGGs may also contribute to the favorable prognosis of this subgroup of patients.
- Published
- 2014
37. Association of genetic variants in the retinoblastoma binding protein 6 gene with the risk of glioma: a case-control study in a Chinese Han population.
- Author
-
Hu D, Zhang S, Zhao Y, Wang S, Wang Q, Song X, Lu D, Mao Y, and Chen H
- Subjects
- Adult, Aged, Asian People, Case-Control Studies, China epidemiology, Female, Genetic Association Studies, Genotype, Haplotypes, Humans, Male, Middle Aged, Polymorphism, Single Nucleotide genetics, Risk, Ubiquitin-Protein Ligases, Brain Neoplasms epidemiology, Brain Neoplasms genetics, Carrier Proteins genetics, DNA-Binding Proteins genetics, Glioma epidemiology, Glioma genetics
- Abstract
Object: The retinoblastoma binding protein 6 (RBBP6) gene plays an important role in the induction of apoptosis and regulation of the cell cycle, and interacts with both p53 and retinoblastoma protein in carcinogenesis. Recently, many studies investigating the function of the RBBP6 gene, including its roles in lung cancer and breast cancer, have been reported. However, the association between RBBP6 variants and glioma was unknown. Therefore, to uncover the association between single nucleotide polymorphisms (SNPs) of RBBP6 and glioma, a hospital-based case-control study was performed in a Chinese Han population., Methods: Ten common tagging SNPs of the RBBP6 gene (covering 100% of all SNPs) were genotyped with the Sequenom MassARRY iPLEX platform, including 992 cases and 1008 controls, according to the HapMap database based on a pairwise linkage disequilibrium r(2) threshold of 0.8, minor allele frequency of 0.05, and Hardy-Weinberg equilibrium of 0.05., Results: The authors found that 4 SNPs were significantly associated with glioma (rs2033214, p = 0.013, adjusted OR 2.46, 95% CI 1.18-5.14; rs11860248, p = 8.64 × 10-(6), adjusted OR 1.59, 95% CI 1.23-2.05; rs9933544, p = 3.65 × 10(-4), adjusted OR 1.39, 95% CI 1.13-1.87; rs13332653, p = 0.004, adjusted OR 1.49, 95% CI 1.14-1.95). Stratification analyses revealed that rs2033214 was only significantly associated with low-grade gliomas; rs9933544 and rs13332653 were only significantly associated with glioblastoma multiforme; and rs11860248 was significantly associated with both low-grade gliomas and glioblastoma multiforme, compared with the common wild-type homozygous genotype. Further stratified analysis revealed that rs11860248 was more pronounced in certain subgroups: adults, males, histological types, and family history of cancer. What's more, the haplotype and diplotype analyses consistently revealed that the subjects carrying 1 copy of haplotype CCGCC had a 53% increased glioma risk compared with their corresponding noncarriers (p = 0.018, adjusted OR 1.53, 95% CI 1.08-2.17)., Conclusions: The authors' results suggested that RBBP6 gene variants are associated with glioma and contribute to glioma susceptibility, which was first reported elsewhere. Individuals with the so-called risk alleles might have an increased risk of glioma. These results might provide new insight into the occurrence of glioma.
- Published
- 2014
- Full Text
- View/download PDF
38. [Long-term use of mobile phone and its association with glioma: a systematic review and meta-analysis].
- Author
-
Gong X, Wu J, Mao Y, and Zhou L
- Subjects
- Brain Neoplasms, Humans, Neoplasm Grading, Odds Ratio, Prospective Studies, Cell Phone, Glioma
- Abstract
Objective: The hypothesis that "cell phone induces brain tumor" has become a target of much controversy for several decades and is still a matter of debate even now. We aim to make a systematic review and meta-analysis based on published studies on glioma to identify current evidences for evaluating mobile phones and glioma risk, especially on long-term use of mobile phones., Methods: The study was conducted according to the Cochrane systematic review methods and reported according to the PRISMA (Preferred Reporting Items for Systematic reviews and Meta-Analyses) statement according to a prospective research protocol accessed via http://www.crd.york.ac.uk/prospero. The software RevMan 5 was used for statistic analysis. Latency and lateralization were used for the examining the dose-response relationship., Results: Overall evidence suggested the increased risk of glioma among long-term ipsilateral users of mobile phone with an odds ratio (OR) of 1.46[1.12, 1.92] based on meta-analysis. Especially, for low-grade glioma, long-term use yielded an OR value of 2.27 [1.81, 2.85]., Conclusion: The evidence is currently insufficient on this issue, especially on long-term use of mobile phone. Neither a definite answer nor a clear explanation may be offered for the relationship. And larger prospective trials are warranted.
- Published
- 2014
39. 3.0-T intraoperative magnetic resonance imaging-guided resection in cerebral glioma surgery: interim analysis of a prospective, randomized, triple-blind, parallel-controlled trial.
- Author
-
Wu JS, Gong X, Song YY, Zhuang DX, Yao CJ, Qiu TM, Lu JF, Zhang J, Zhu W, Mao Y, and Zhou LF
- Subjects
- Adult, Brain Neoplasms mortality, Female, Glioma mortality, Humans, Kaplan-Meier Estimate, Male, Middle Aged, Proportional Hazards Models, Prospective Studies, Brain Neoplasms surgery, Glioma surgery, Magnetic Resonance Imaging methods, Neuronavigation methods, Surgery, Computer-Assisted methods
- Published
- 2014
- Full Text
- View/download PDF
40. Increased expression of Capn4 is associated with the malignancy of human glioma.
- Author
-
Cai JJ, Qi ZX, Hua W, Zhu JJ, Zhang X, Yao Y, and Mao Y
- Subjects
- Adolescent, Adult, Aged, Calpain genetics, Cell Line, Tumor, Cell Movement physiology, Cell Proliferation drug effects, Cell Proliferation physiology, Female, Follow-Up Studies, Humans, Male, Middle Aged, Neoplasm Invasiveness, RNA, Small Interfering genetics, RNA, Small Interfering metabolism, Severity of Illness Index, Statistics, Nonparametric, Tissue Array Analysis, Wound Healing, Young Adult, Brain Neoplasms metabolism, Brain Neoplasms pathology, Calpain metabolism, Glioma metabolism, Glioma pathology
- Abstract
Aims: Recent evidence indicates that the increased expression of calpain small subunit 1 (Capn4) is associated with tumorigenesis. This study was designed to explore the role which Capn4 plays in human glioma., Methods: We detected the expression of Capn4 by immunohistochemistry in tissue microarrays and tissue samples. Following the down-regulation of Capn4 in glioma cell lines by a specific short hairpin RNA, the function of Capn4 in invasion, migration, and proliferation was assessed. We then evaluated the prognostic role of Capn4 using univariate and multivariate analysis in 94 glioblastoma (GBM) patients., Results: Glioma tissues exhibited notably higher expression of Capn4 compared with control brain tissues and was positively correlated with histological malignancy. The down-regulation of Capn4 in glioma cells led to a decrease in invasion and migration in vitro. Through univariate analysis, the prognosis of GBM patients with Capn4 overexpression was significantly poorer with respect to progression-free survival (PFS) and overall survival (OS). Based on the results of the multivariate analysis, Capn4(high) was demonstrated to be a negative independent prognostic indicator for PFS and OS in GBM patients., Conclusion: The overexpression of Capn4 is a novel negative prognostic marker, and Capn4 may be used as a new target in therapeutic strategies for human glioma., (© 2014 John Wiley & Sons Ltd.)
- Published
- 2014
- Full Text
- View/download PDF
41. Mouse glioma immunotherapy mediated by A2B5+ GL261 cell lysate-pulsed dendritic cells.
- Author
-
Xu M, Yao Y, Hua W, Wu Z, Zhong P, Mao Y, Zhou L, Luo F, and Chu Y
- Subjects
- Animals, Brain Neoplasms immunology, Cancer Vaccines therapeutic use, Cell Line, Tumor, Disease Models, Animal, Flow Cytometry, Glioma immunology, Glioma pathology, Mice, Mice, Inbred C57BL, Statistics, Nonparametric, T-Lymphocytes, Cytotoxic, Time Factors, Xenograft Model Antitumor Assays, Brain Neoplasms therapy, Dendritic Cells immunology, Gangliosides metabolism, Glioma therapy, Immunotherapy methods, Tissue Extracts therapeutic use
- Abstract
Immunotherapy strategies targeting glioma stem-like cells (GSCs) hold promise for improving outcomes in glioblastoma patients. We used the A2B5 monoclonal antibody to classify GSCs derived from the mouse GL261 glioma cell line, and A2B5+ GL261 cell lysate-pulsed dendritic cells (DCs) were used to treat mouse glioma. We found that such DCs elicited a stronger specific cytotoxic T lymphocyte response against A2B5+ GL261 cells than A2B5- GL261 cell lysate-pulsed DCs. The effect of A2B5+ GL261 cell lysate-pulsed DCs in vivo depended on when the vaccination was started. In the tumor cell adaptation phase, C57BL/6 mice had an immune response against GL261, and vaccination enhanced the immune response and prevented glioma formation in 37.5% of mice. In contrast, after glioma formation, the immune response against GL261 was decreased, and vaccination had no therapeutic effect. Our findings suggest that vaccination with A2B5+ GL261 cell lysate-pulsed DCs only has some glioma preventive effect.
- Published
- 2014
- Full Text
- View/download PDF
42. Glioma-associated antigen HEATR1 induces functional cytotoxic T lymphocytes in patients with glioma.
- Author
-
Wu ZB, Qiu C, Zhang AL, Cai L, Lin SJ, Yao Y, Tang QS, Xu M, Hua W, Chu YW, Mao Y, Zhu JH, Xu J, and Zhou LF
- Subjects
- Adolescent, Adult, Aged, Cell Line, Tumor, Cytotoxicity, Immunologic, Epitopes, T-Lymphocyte chemistry, Epitopes, T-Lymphocyte immunology, Epitopes, T-Lymphocyte metabolism, Female, Gene Expression, Glioma metabolism, Glioma pathology, HLA-A Antigens immunology, HLA-A Antigens metabolism, Humans, Interferon-gamma metabolism, Male, Middle Aged, Minor Histocompatibility Antigens, Neoplasm Grading, Peptides chemistry, Peptides metabolism, Protein Binding immunology, RNA-Binding Proteins chemistry, RNA-Binding Proteins metabolism, Young Adult, Glioma genetics, Glioma immunology, RNA-Binding Proteins genetics, T-Lymphocytes, Cytotoxic immunology, T-Lymphocytes, Cytotoxic metabolism
- Abstract
A2B5+ glioblastoma (GBM) cells have glioma stem-like cell (GSC) properties that are crucial to chemotherapy resistance and GBM relapse. T-cell-based antigens derived from A2B5+ GBM cells provide important information for immunotherapy. Here, we show that HEAT repeat containing 1 (HEATR1) expression in GBM tissues was significantly higher than that in control brain tissues. Furthermore, HEATR1 expression in A2B5+ U87 cells was higher than that in A2B5-U87 cells (P = 0.016). Six peptides of HEATR1 presented by HLA-A∗02 were selected for testing of their ability to induce T-cell responses in patients with GBM. When peripheral blood mononuclear cells from healthy donors (n = 6) and patients with glioma (n = 33) were stimulated with the peptide mixture, eight patients with malignant gliomas had positive reactivity with a significantly increased number of responding T-cells. The peptides HEATR(1682-690), HEATR(11126-1134), and HEATR(1757-765) had high affinity for binding to HLA-A∗02:01 and a strong capacity to induce CTL response. CTLs against HEATR1 peptides were capable of recognizing and lysing GBM cells and GSCs. These data are the first to demonstrate that HEATR1 could induce specific CTL responses targeting both GBM cells and GSCs, implicating that HEATR1 peptide-based immunotherapy could be a novel promising strategy for treating patients with GBM.
- Published
- 2014
- Full Text
- View/download PDF
43. B7-H4 expression is elevated in human U251 glioma stem-like cells and is inducible in monocytes cultured with U251 stem-like cell conditioned medium.
- Author
-
Mo LJ, Ye HX, Mao Y, Yao Y, and Zhang JM
- Subjects
- AC133 Antigen, Antigens, CD metabolism, Brain Neoplasms pathology, Cell Line, Tumor, Cells, Cultured, Culture Media, Conditioned, Culture Media, Serum-Free, Gene Expression Regulation, Neoplastic, Glial Fibrillary Acidic Protein metabolism, Glioma pathology, Glycoproteins metabolism, Humans, Monocytes cytology, Neoplastic Stem Cells pathology, Nestin metabolism, Peptides metabolism, SOXB1 Transcription Factors metabolism, Brain Neoplasms metabolism, Glioma metabolism, Monocytes metabolism, Neoplastic Stem Cells metabolism, V-Set Domain-Containing T-Cell Activation Inhibitor 1 metabolism
- Abstract
Previous studies indicated that B7-H4, the youngest B7 family, negatively regulates T cell-mediated immunity and is significantly overexpressed in many human tumors. Tumor stem cells are purported to play a role in tumor renewal and resistance to radiation and chemotherapy. However, the link between B7-H4 and tumor stem cells is unclear. In this study, we investigated B7-H4 expression in the medium of human glioma U251 cell cultures. Immunofluorescence results showed that U251 cells cultured in serum-free medium (supplemented with 2% B27, 20 ng/mL epidermal growth factor, 20 ng/mL basic fibroblast growth factor) maintained stem-like cell characteristics, including expression of stem cell marker CD133 and the neural progenitor cell markers nestin and SOX2. In contrast, U251 cells cultured in serum-containing medium highly expressed differentiation marker glial fibrillary acidic protein. Flow cytometry analysis showed serum-free medium-cultured U251 cells expressed higher intracellular B7-H4 than serum-containing medium-cultured U251 cells (24%-35% vs. 8%-11%, P < 0.001). Immunofluorescence in purified monocytes from normal human peripheral blood mononuclear cells revealed moderate expression of B7-H4 after stimulation with conditioned medium from U251 cells cultured in serum-containing medium. Moreover, conditioned medium from U251 stem-like cells had a significant stimulation effect on B7-H4 expression compared with serum-containing conditioned medium (P < 0.01). Negative costimulatory molecule B7-H4 was preferentially expressed in U251 stem-like cells, and conditioned medium from these cells more effectively induced monocytes to express B7-H4 than conditioned medium from U251 cells cultured in the presence of serum. Our results show that U251 stem-like cells may play a more crucial role in tumor immunoloregulation with high expression of B7-H4.
- Published
- 2013
- Full Text
- View/download PDF
44. Awake language mapping and 3-Tesla intraoperative MRI-guided volumetric resection for gliomas in language areas.
- Author
-
Lu J, Wu J, Yao C, Zhuang D, Qiu T, Hu X, Zhang J, Gong X, Liang W, Mao Y, and Zhou L
- Subjects
- Adult, Aged, Brain Neoplasms surgery, Female, Glioma surgery, Humans, Male, Middle Aged, Neuronavigation methods, Prospective Studies, Wakefulness physiology, Young Adult, Brain Mapping methods, Brain Neoplasms diagnosis, Glioma diagnosis, Language, Magnetic Resonance Imaging methods, Monitoring, Intraoperative methods
- Abstract
The use of both awake surgery and intraoperative MRI (iMRI) has been reported to optimize the maximal safe resection of gliomas. However, there has been little research into combining these two demanding procedures. We report our unique experience with, and methodology of, awake surgery in a movable iMRI system, and we quantitatively evaluate the contribution of the combination on the extent of resection (EOR) and functional outcome of patients with gliomas involving language areas. From March 2011 to November 2011, 30 consecutive patients who underwent awake surgery with iMRI guidance were prospectively investigated. The EOR was assessed by volumetric analysis. Language assessment was conducted before surgery and 1 week, 1 month, 3 months and 6 months after surgery using the Aphasia Battery of Chinese. Awake language mapping integrated with 3.0 Tesla iMRI was safely performed for all patients. An additional resection was conducted in 11 of 30 patients (36.7%) after iMRI. The median EOR significantly increased from 92.5% (range, 75.1-97.0%) to 100% (range, 92.6-100%) as a result of iMRI (p<0.01). Gross total resection was achieved in 18 patients (60.0%), and in seven of those patients (23.3%), the gross total resection could be attributed to iMRI. A total of 12 patients (40.0%) suffered from transient language deficits; however, only one (3.3%) patient developed a permanent deficit. This study demonstrates the potential utility of combining awake craniotomy with iMRI; it is safe and reliable to perform awake surgery using a movable iMRI., (Copyright © 2013 Elsevier Ltd. All rights reserved.)
- Published
- 2013
- Full Text
- View/download PDF
45. Genetic variants in SLC7A7 are associated with risk of glioma in a Chinese population.
- Author
-
Fan S, Zhao Y, Li X, Du Y, Wang J, Song X, Zhou F, Chen H, Chen G, Zhao Y, Mao Y, and Lan Q
- Subjects
- Adolescent, Adult, Aged, Aged, 80 and over, Amino Acid Transport System y+L, Female, Gene Frequency, Genetic Association Studies, Genetic Predisposition to Disease, Genotype, Humans, Male, Middle Aged, Multivariate Analysis, Odds Ratio, Brain Neoplasms genetics, Fusion Regulatory Protein 1, Light Chains genetics, Glioma genetics, Polymorphism, Single Nucleotide
- Abstract
Dysregulation of the amino acid transporter SLC7A7 is involved in multiple types of cancer including gliobastoma (GBM), the most malignant form of glioma. We hypothesized that SLC7A7 genetic variants may influence glioma risk. To test this hypothesis, we conducted a case-control study in 736 incident glioma cases and 793 cancer-free controls in a Chinese population by genotyping 22 common single nucleotide polymorphisms in SLC7A7. In single-locus analysis, we found an increased risk was associated with the variant genotypes of rs12888930 (adjusted odds ratio [OR] = 1.25, 95% confidence interval [CI] 1.02-1.54, P = 0.034), rs12433985 (adjusted OR = 1.38, 95%CI = 1.13-1.70), rs2065134 (adjusted OR = 1.43, 95% CI 1.05-1.95) in a dominant genetic model and rs12436190 (adjusted OR = 1.37, 95%CI 1.06-1.77) in a recessive model. Multivariate analysis confirmed that rs12433985 and rs2065134 were significant and independent risk factor for glioma as well as GBM subtype (for rs12433985, OR = 1.21, 95%CI 1.04-1.42, P = 0.016 for all types of gliomas and P = 0.013, OR = 1.30, 95%CI 1.06-1.60 for GBM. For rs2065134, OR = 1.39, 95%CI 1.02-1.89, P = 0.039 for all types of gliomas and OR = 1.66, 95%CI 1.12-2.24, P = 0.011). These results, for the first time, provide suggestive evidence of polymorphisms in SLC7A7 is involved in the aetiology of glioma.
- Published
- 2013
- Full Text
- View/download PDF
46. Olig2-positive cells in glioneuronal tumors show both glial and neuronal characters: the implication of a common progenitor cell?
- Author
-
Matsumura N, Yokoo H, Mao Y, Yin W, and Nakazato Y
- Subjects
- Adolescent, Adult, Aged, Aged, 80 and over, Brain Neoplasms pathology, Brain Neoplasms ultrastructure, Child, Child, Preschool, Female, Glioma pathology, Glioma ultrastructure, Humans, Immunohistochemistry, In Situ Hybridization, Fluorescence, Male, Microscopy, Electron, Middle Aged, Oligodendrocyte Transcription Factor 2, Oligodendroglia pathology, Rosette Formation, Young Adult, Basic Helix-Loop-Helix Transcription Factors genetics, Brain Neoplasms genetics, Glioma genetics, Nerve Tissue Proteins genetics, Neuroglia pathology, Neurons pathology, Stem Cells pathology
- Abstract
Glioneuronal tumors (GNTs) are rare neoplasms consisting of both glial and neuronal components. Among the GNTs, dysembryoplastic neuroepithelial tumors (DNTs), papillary glioneuronal tumors (PGNTs), and rosette-forming glioneuronal tumors of the fourth ventricle (RGNTs) share the character of being mainly composed of small round Olig2-positive tumor cells. Using immunohistochemistry and fluorescence in situ hybridization, we examined a series of 35 GNT cases (11 DNTs, 15 PGNTs and 9 RGNTs) on the characteristics of Olig2-positive tumor cells. Histologically, Olig2-positive cells showed small round forms in most GNTs; however, there were a small number of Olig2-positive cells with neuronal morphology only in a PGNT case. These cells expressed both glial and neuronal markers by double immunostaining. With regard to labeling indices and intensity, only PGNT cells expressed neuronal markers, including α-internexin and neurofilament. These findings also suggest that some Olig2-positive PGNT cells may show neuronal differentiation. In GNTs, a considerable number of Olig2-positive cells showed immunopositivity for cyclin D1 and/or platelet-derived growth factor receptor alpha (PDGFRα), which are markers for oligodendrocyte progenitor cells. These immunostainings were particularly strong in DNTs. In RGNTs, Olig2-positive cells formed "neurocytic rosettes". Furthermore, they were also immunopositive for glial markers, including GFAP, PDGFRα and cyclin D1. These findings indicate the heterogeneous characteristics of Olig2-positive cells in GNTs, and some of them also exhibited neuronal features. So it is possible that a part of Olig2-positive GNT cells have characteristics similar to those of progenitor cells., (© 2012 Japanese Society of Neuropathology.)
- Published
- 2013
- Full Text
- View/download PDF
47. [Prognostic evaluations of recurrent gliomas and preliminary efficacies of combined modality therapy].
- Author
-
Zhang X, Yao Y, Qin ZY, Wang Y, Wu JS, Mao Y, and Zhou LF
- Subjects
- Adult, Aged, Combined Modality Therapy, Female, Humans, Male, Middle Aged, Prognosis, Survival Rate, Young Adult, Glioma pathology, Glioma therapy, Neoplasm Recurrence, Local therapy
- Abstract
Objective: To evaluate the prognosis and efficacies of comprehensive treatment for recurrent gliomas., Methods: A total of 62 patients diagnosed as recurrent gliomas at our hospital between May 2007 and January 2012 were reviewed and analyzed. The investigators compared the prognosis of different grades of gliomas and evaluated the efficacies of combined modality therapy of surgery, radiotherapy, chemotherapy and immunotherapy., Results: Their median periods of time-to-progression (TTP) and overall survival (OS) were 6.0 and 13.0 months respectively. The median TTP of WHO grade II (n = 21), III (n = 13) and IV (n = 28) recurrent gliomas were 9.0, 9.0 and 5.0 months respectively. And the average OS of WHO grade II, III and IV recurrent gliomas were 26.6, 21.4 and 13.8 months respectively. The efficacious rate of chemotherapy was 26.7%., Conclusion: Combined modality therapy based on chemotherapy may moderately improve the prognosis of recurrent gliomas. And the pathological grades of primary tumors are correlated with the prognosis of recurrent gliomas.
- Published
- 2013
48. Clinical application of motor pathway mapping using diffusion tensor imaging tractography and intraoperative direct subcortical stimulation in cerebral glioma surgery: a prospective cohort study.
- Author
-
Zhu FP, Wu JS, Song YY, Yao CJ, Zhuang DX, Xu G, Tang WJ, Qin ZY, Mao Y, and Zhou LF
- Subjects
- Adolescent, Adult, Aged, Brain Mapping, Brain Neoplasms pathology, Child, Cohort Studies, Efferent Pathways surgery, Electric Stimulation, Electromyography, Evoked Potentials, Motor physiology, Female, Glioma pathology, Humans, Imaging, Three-Dimensional, Male, Middle Aged, Neuronavigation, Young Adult, Brain Neoplasms surgery, Diffusion Tensor Imaging, Efferent Pathways physiopathology, Glioma surgery, Monitoring, Intraoperative, Neurosurgical Procedures methods
- Abstract
Background: Glioma surgery in eloquent areas remains a challenge because of the risk of postoperative motor deficits., Objective: To prospectively evaluate the efficiency of using a combination of diffusion tensor imaging (DTI) tractography functional neuronavigation and direct subcortical stimulation (DsCS) to yield a maximally safe resection of cerebral glioma in eloquent areas., Methods: A prospective cohort study was conducted in 58 subjects with an initial diagnosis of primary cerebral glioma within or adjacent to the pyramidal tract (PT). The white matter beneath the resection cavity was stimulated along the PT, which was visualized with DTI tractography. The intercept between the PT border and DsCS site was measured. The sensitivity and specificity of DTI tractography for PT mapping were evaluated. The efficiency of the combined use of both techniques on motor function preservation was assessed., Results: Postoperative analysis showed gross total resection in 40 patients (69.0%). Seventeen patients (29.3%) experienced postoperative worsening; 1-month motor deficit was observed in 6 subjects (10.3%). DsCS verified a high concordance rate with DTI tractography for PT mapping. The sensitivity and specificity of DTI were 92.6% and 93.2%, respectively. The intercepts between positive DsCS sites and imaged PTs were 2.0 to 14.7 mm (5.2 ± 2.2 mm). The 6-month Karnofsky performance scale scores in 50 postoperative subjects were significantly increased compared with their preoperative scores., Conclusion: DTI tractography is effective but not completely reliable in delineating the descending motor pathways. Integration of DTI and DsCS favors patient-specific surgery for cerebral glioma in eloquent areas.
- Published
- 2012
- Full Text
- View/download PDF
49. Fine-mapping of a region of chromosome 5p15.33 (TERT-CLPTM1L) suggests a novel locus in TERT and a CLPTM1L haplotype are associated with glioma susceptibility in a Chinese population.
- Author
-
Zhao Y, Chen G, Zhao Y, Song X, Chen H, Mao Y, and Lu D
- Subjects
- Adolescent, Adult, Asian People, Child, China, Female, Humans, Linkage Disequilibrium, Male, Middle Aged, Polymorphism, Single Nucleotide, Young Adult, Brain Neoplasms genetics, Chromosomes, Human, Pair 5, Genetic Predisposition to Disease, Glioma genetics, Haplotypes, Membrane Proteins genetics, Neoplasm Proteins genetics, Telomerase genetics
- Abstract
Two genome-wide association studies (GWAS) have identified 5p15.33 (TERT-CLPTM1L) as one of the susceptible regions for glioma in European background. A replication research of our group highlighted the association signals in the TERT gene of this region in a Chinese Han population. To comprehensively explore the region of glioma association at 5p15.33 and to refine the potential causal variants to a smaller critical region, we conducted a fine-mapping association study among 983 cases and 1,024 controls in a Chinese Han population. Using Hapmap3 datasets as a reference, we genotyped 16 tag SNPs across this 87.9-kb region encompassing TERT. Significant association with glioma risk was observed for rs2853677 [GG vs. GA: adjusted OR = 1.46, p = 5.51 × 10(-6), GG vs. AA: adjusted OR = 1.72, p = 7.64 × 10(-6), GG vs. GA and AA: adjusted OR = 1.96, p = 6.8 × 10(-6)] in TERT and an uncommon CLPTM1L haplotype G-T-A of rs4635969, rs6554759 and rs414965 (haplotype frequency = 0.07) was associated with higher glioma risk compared with the most common G-C-G haplotype (adjusted OR = 1.44, simulated p = 6.00 × 10(-3) under additive model). Our results indicate that sequence variants in the region flanking rs2853677 may account for the GWAS and replication signals identified in 5p15.33 for glioma susceptibility in Chinese population; besides, haplotype G-T-A in CLPTM1L also confers a risk to glioma suggesting CLPTM1L is also involved in the etiology of glioma. Additional studies especially those taking advantage of sequencing platforms are warranted to further confirm the conclusions and go deeper with our findings., (Copyright © 2012 UICC.)
- Published
- 2012
- Full Text
- View/download PDF
50. Single nucleotide polymorphisms of matrix metallopeptidase 3 and risk of gliomas in a Chinese Han population.
- Author
-
Fan W, Zhou K, Hu D, Song X, Zhao Y, Chen H, Wei Q, Chen G, Shi J, Du G, Mao Y, Lu D, and Zhou L
- Subjects
- Adult, Asian People genetics, Case-Control Studies, China, Female, Haplotypes genetics, Humans, Male, Middle Aged, Odds Ratio, Promoter Regions, Genetic, Risk Factors, Central Nervous System Neoplasms genetics, Genetic Predisposition to Disease, Glioma genetics, Matrix Metalloproteinase 3 genetics, Polymorphism, Single Nucleotide
- Abstract
Matrix metallopeptidases (MMPs) play an important role in central nervous system tumor growth, invasion and spreading. The currently available data provide clear evidence for the involvement of MMP3 in the pathophysiology of glioma. The study aims to explore the association of single nucleotide polymorphisms (SNPs) across the MMP3 gene with glioma risk. Three haplotype tagging and additional two promoter SNPs were genotyped among 766 glioma patients and 824 cancer-free controls from East China. None of these polymorphisms alone had a significant effect on risk of gliomas. However, when three promoter polymorphisms were evaluated together by the number of putative risk of genotypes (i.e., rs645419AA, 632478CA+AA, rs522616AA), a statistically significantly increased risk of gliomas was associated with the combined genotypes with two to three risk genotypes, compared with those with zero to one risk genotypes (adjusted odds ratio (OR) = 1.32; 95% confidence interval (CI) = 1.03-1.68). This increased risk was also more pronounced among adults (adjusted OR = 1.14, 95%CI = 1.02-1.27), males (adjusted OR = 1.19, 95%CI = 1.05-1.36), smokers (adjusted OR = 1.28, 95%CI = 1.07-1.52), subjects with no family history of cancer (adjusted OR = 1.21, 95%CI = 1.07-1.37), and patients with nonastrocytic gliomas (adjusted OR = 1.23, 95%CI = 1.06-1.43). In summary, our results suggest that any one of MMP3 variants may not have a substantial effect on glioma risk, but a joint effect of MMP3 promoter polymorphisms may contribute to risk of gliomas, particularly for adult gliomas., (Copyright © 2011 Wiley Periodicals, Inc.)
- Published
- 2012
- Full Text
- View/download PDF
Catalog
Discovery Service for Jio Institute Digital Library
For full access to our library's resources, please sign in.